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ABSTRACT 
MODULATION OF INFLAMMATORY PATHWAY BY INFLAMMATORY 
INHIBITOR (JSH-23) MITIGATES DIABETIC RETINOPATHY 
   Rubens Petit Homme 
August 11, 2020 
Diabetic retinopathy (DR) is the most common microvascular complication of 
diabetes mellitus (DM). Its pathology is consisted of the breakdown of the blood-retinal 
barrier (BRB), particularly the inner blood-retinal barrier (iBRB). The exact mechanism 
that leads to the iBRB impairment and the development of DR has not been elucidated 
yet. However, chronic inflammation that is hallmark of the type I DM has recently 
become a key focus in DR study. Hyperglycemia causes dysregulation of nuclear factor-
kappa B (NF-); and its constant activation increases the expression of inducible nitric 
oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and intercellular adhesion 
molecule-1 (ICAM-1) in the retina and vitreous of DR patients and animal models. This 
increase in inflammatory mediators leads to the degradation of junctional molecules, 
occludin, connexin-43, death of retinal cells via pyroptosis, and thus disruption of the 
iBRB. Derailment of the iBRB induces fluid accumulation into the retina of DR 
patients, which eventually progresses into vision impairment. The purpose of this study 
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is to investigate whether chronic inflammation in DM induces disruption of iBRB; and 
whether inhibition of the expression and activity of NF- by Methyl-N1-(3-phenyl 
propyl) benzene-1, 2-diamine (JSH-23) would mitigate this iBRB disruption.   
Methods: Type 1 diabetic mouse model (Akita) on a C57BL/6J background along with 
non-diabetic littermate were used in the experiments. All mice were 22-24 weeks of age 
at the start of the experiments. The experimental and the control animals were treated for 
four weeks on alternate days with JSH-23 @5mg/Kg body weight. The intraocular 
pressure (IOP), blood pressure, blood glucose, and body weights of all animals were 
measured before and after treatment. Fluorescence angiography (FA), optical coherence 
tomography (OCT), and dark-adapted electroretinogram were performed before and after 
the treatment. Also, intraperitoneal glucose tolerance test (GTT) were performed in the 
animals before and after the treatment. Then, the retinas and plasma were collected. 
Western blotting and real-time polymerase chain reaction were performed to analyze 
protein expression and the mRNA levels of NF- p65, iNOS, COX-2, ICAM-1, 
occludin, connexin-43, NLRP3, caspase-1, and IL-1. Additionally, plasma insulin levels 
were also analyzed via ELISA kit. 
Results: The body weight of Akita mice was significantly lower than the C57BL/6J 
mice. The treatment with JSH-23 did not have any effect on body weight. The blood 
glucose of Akita mice was significantly higher than the blood glucose of non-diabetic 
littermate control mice. The treatment substantially decreased blood glucose in Akita 
mice. Also, the plasma insulin level for the Akita mice was significantly lower 
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compared to non-diabetic littermate control mice. The intraperitoneal 
GTT showed that the Akita mice were unable to lower their blood glucose levels. 
The total and phosphorylated protein expression levels of NF-B p65 were significantly 
decreased after treatment with JSH-23 in Akita mice, and the gene expression of NF-B 
p65 also reduced. The protein and gene expression levels of iNOS, COX-2, and ICAM-1 
were reduced after treatment in Akita mice, and the treatment significantly lowered the 
expression of pyroptosis marker NLRP3.  The gene expression of other proteins in the 
pyroptosis pathway were also reduced, including caspase-1 and IL-1. On the other hand, 
the protein and gene expression levels of junctional molecules occludin, connexin-43 
were significantly increased in Akita mice after treatment with JSH-23. 
The blood pressure of the animals was normal and the treatment did not have any effect 
on the blood pressure. FA depicted an increase in retinal capillary permeability in Akita 
mice, and the treatment significantly reduced that permeability. The OCT showed retinal 
layers thickening in the retina of Akita mice, and treatment increased the retinal layers 
thickness. Electroretinogram (ERG) showed an increase in the amplitude of the A-wave 
and the B-wave in Akita mice. 
Conclusions: The results showed that inhibitor (JSH-23) improved visual function by 
decreasing the retinal vascular permeability, IOP, and the retinal inflammation in Akita 
mice. 
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         CHAPTER I 
 GENERAL INTRODUCTION 
Retina 
Phototransduction carried out by retinal neuronal cells, supported by retinal glial 
cells (RGC), is the primary function of the retina [1-4]. Phototransduction is divided into 
three parts: a receptor (rhodopsin), G-protein (transducin), and an effector (cGMP 
phosphodiesterase or PDE/PDE6). It starts with 11-cis retinal absorption of a photon that 
leads to a conformational change in 11-cis retinal to 11-trans retinal. Rhodopsin is 
activated (metarhodopsin II), which then enables transducin [3, 5]. 
Transducin activate cGMP phosphodiesterase (PDE). PDE, hydrolyze cGMP, 
lead to the closing of a cGMP-gated ion channel in the membrane. PDE decreases cGMP 
concentration; as a result, the cGMP-dependent gated channels in the plasma membrane 
closed. Uptake of cation reduces in the photoreceptor outer segment (POS); the 
membrane hyperpolarizes. That decreases the secretion of glutamate. Termination of 
phototransduction involves inactivation of rhodopsin, transducin, PDE, and increasing 
concentration of cGMP. Rhodopsin kinase (GRK1) phosphorylated rhodopsin; protein 
arrestin (Arr1) complete the inactivation by binding to the receptor [6, 7]. G-PDE 
inactivated by RGS9-1- G-protein signaling protein [8]; Guanylyl cyclase restored the 
concentration of cGMP [9, 10]. 
The vision cycle is divided into dark and light periods. The dark period leads to a 
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constant flow of Na+ into the photoreceptor, thus depolarizing the plasma membrane. 
Depolarization triggers the release of glutamate however during the light cycle, the 
opposite happens, the flow of Na+ stops, and thus the plasma membrane hyperpolarizes 
and the glutamate secretion stops [11-13]. 
Rods photoreceptors are sensitive to blue-green light (peak ~ 500 nm 
wavelengths). In fact, they are very sensitive and at the same time highly efficient in 
capturing a single photon [14]. Visual pigments in cones are the opsin molecules, and 
cones sensitivity depends on the molecular structure of opsin for the long wavelengths 
(red light), short-wavelength (blue light), and medium wavelength (green light). 
Anatomy and Physiology of the Retina 
The retina is a semi-circle with a diameter between 30 and 40 mm, 0.5 mm 
thickness, lining the posterior part of the eye. All the major blood vessels of the retina 
converge towards the center to form the optic nerve. The foveal (the center of the macula) 
contains no blood vessels and only cone photoreceptors are located to the left of the optic 
nerve. The retina is divided into two areas: the central (macula) and the peripheral retina. 
The central retina is the circular area with a 6 mm diameter from the fovea, while the 
peripheral retina is everything outside of the central retina [15].  
The retina is further divided into ten different layers of cells and cell bodies such 
as outer nuclear layer (ONL), inner nuclear layer (INL), inner plexiform layer (IPL), 
outer plexiform layer (OPL),  ganglion cell layer (GCL), outer limiting membrane 
(OLM), nerve fiber layers (NFL), inner limiting membrane (ILM), and the retinal 
pigment epithelium (RPE). The cell layers contain ganglion, photoreceptors, and 
epithelial cells. The ganglion cells (GCs) are closest to the retina and serves as the output 




light, while the epithelial performs many functions to maintain retinal homeostasis.  
 The cell bodies of first-order neurons (rods and cones photoreceptors) reside in  
the ONL. The INL houses the cell bodies of second-order neurons (bipolar, horizontal, 
and amacrine cells).  First-order and second-order neurons synapse in the OPL. GCs and 
second-order neurons synapse in the IPL. The OLM contains adherens junctions between 
photoreceptors and Müller cells, while the ILM houses the Müller cells. The OLM forms 
a barrier between the outer retina and the subretinal space, while the ILM forms a barrier 
between the inner retina and the vitreous humor. All retinal cell layers are perfused 
mainly by the central retinal artery (CRA).  
The retina has two main blood supplies: choroid (perfused photoreceptors) 
responsible for about ¾ of retinal blood supply, and the CRA (perfused inner retina), 
responsible for the last ¼ of the retinal blood supply [16]. The retinal layers are perfused 
via retinal capillaries. The retinal capillaries form a network throughout the retina, radial 
peripapillary capillaries (RPCs), inner and outer layer capillaries. The RPCs is located 
within the NFL and is alimented about 5 mm from the optic disc, inner capillaries 
alimented the GCL, while the outer capillary aliments the IPL, OPL, and the INL [16, 
17].  
 
Outer Plexiform Layer (OPL). Second-order neurons synapses with photoreceptors in the 
OPL to propagate the signals. The OPL contains mainly two types of cells: bipolar and 
horizontal cells. The retina contains 11 different types of bipolar cells, all except one 
synapse with cones photoreceptors [18-21]. Bipolar cell bodies reside in the INL, with 
dendrites located in the OPL. Some photoreceptors synapse with one bipolar cell while 
other with many bipolar cells. There are also some bipolar cells that are photoreceptors 
specific, e.g., S-cone. Bipolar cells designated as either ON or OFF [19]. Bipolar cells 
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responded differently to glutamate. Based on the receptor, it could lead to depolarization 
or hyperpolarization of the plasma membrane. Depolarization indicates an ON-bipolar 
cell, while hyperpolarization indicates an OFF-bipolar cell [22].  The ON-bipolar cell has 
mGluR6 glutamate receptors [23, 24] while OFF-bipolar cell has iGluR AMPA-kainate 
glutamate receptors [25]. The retina has only two distinct types of horizontal cells, which 
are layered horizontally in the OPL [21]. In the presence of glutamate, horizontal cells 
hyperpolarize. The IPL further carries the signal to amacrine and GCs. 
Inner Plexiform Layer (IPL). Bipolar cells synapse with amacrine and GCs within the 
IPL. There are various types of amacrine cells [19, 26]. They used serotonin, 
acetylcholine, and other neurotransmitters for further transducing phototransduction 
towards GCs [27-29]. They are various types of GCs as well [30, 31]. GCs are divided 
into alpha, beta, gamma, and G4 to G23 [31]. Beta GCs are the most prevalent, 
approximately half of all the GCs [32, 33]. The IPL separates the ON-bipolar and OFF-
bipolar cells by dividing the GCs into two compartments below the amacrine cells. The 
ON-bipolar cells interact only with a compartment while the OFF-bipolar cells interact 
with the other compartment [34-39]. The optic nerve synapses with the GCs and sends 
the information to the brain. 
Visual Responses of Ganglion Cells. Similar to bipolar cells, GCs are divided into ON, 
OFF, and ON-OFF centers cells based on their response to light. ON-GCs fires a burst of 
action potential (AP) upon stimulation then maintain the firing at a short interval. ON-
OFF-GCs fires AP when activated and then at the end of the stimulus, while OFF-GCs 
centers fire AP at the end of the stimulus [40, 41]. OFF-GCs cells synapse with axon 
terminal of OFF-bipolar cells in the proximity of the amacrine cell bodies, ON-GCs cells 
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synapses with ON-bipolar cells, while ON-OFF cells do both [36, 42]. As stated earlier, 
GCs receive the final output of the signals, and they then send that output through the 
brain via the optic nerve for interpretation. Another structure critical to retinal function is 
the RPE. 
Retinal Pigment Epithelium. The RPE located between the choroid and the POS. RPE 
apical side faces the POS, while its basolateral side faces the Bruch’s Membrane. It has 
pigments granules in a single sheet of cell shape that resembles a hexagon that links 
together via tight junctions. The RPE contains organelles capable of digesting POS into 
phagosomes. The RPE functions to absorb light, buffer ion, phagocytoses, epithelial 
transport, secretion, and immune modulation. 
Phototransduction results in a high amount of photo-oxidative energy within the 
retina [63, 110]. The RPE located in the middle of the outer retinal blood flow (choroid) 
[117]. The choroid perfuses substantially higher than the kidney [111, 112], while the 
retina extraction of oxygen is significantly low, thus the choroidal venous blood is 90% 
saturated with oxygen. RPE also phagocytoses POS. These factors increase the free 
radicals levels in the RPE [63, 110]. RPE uses pigmented granules to defend itself from 
the oxidative stress (OS) [113] that move to the apical side during light absorption [114, 
115]. Aside from the pigmented granules, RPE uses antioxidants, and it has a high 
capacity to repaired macromolecules such as lipids, DNA, and proteins that damaged due 
to an increase of OS in the retina [113, 116]. 
The RPE separates the systemic and the subretinal flow, facilitates the transport 
of nutrients to the retina, balances the ion in the retinal space, and removes metabolic 
wastes from the retina. It also transports key phototransduction metabolites to the retina 
such as glucose, retinal (retinaldehyde; a form of vitamin A), and -3 fatty acids. 
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Apical and basolateral glucose transporter 1 (inducible to meet metabolic needs) 
and glucose transporter 3 facilitate glucose transport into the retina [118]. Retinal 
transportation initiates with retinal uptake and then induces in the visual cycle—
absorption of 22:63 fatty are acids used to transport -3 fatty acid. The 22:63 fatty 
acids are also used to synthesize glycerophospholipids for incorporation into the 
membrane of photoreceptors [119]. 
The retina contains the highest cell density of any tissue in the human body and 
its cells have a substantial metabolic turn-over, which increases the production of water 
and thus its accumulation into the retina. Also, intraocular pressure (IOP) orient 
movement of water towards the retina, further contributing to its accumulation into the 
retina. There is also a substantial production of lactic acid in the retina (19 mM) due to 
retinal metabolic activity [121]. RPE remove water via active transport through 
aquaporin-1 located both in the apical and basolateral membrane of the RPE [122, 123]. 
The energy for that transport is obtained via the ubiquitous Na+/K+ pump located on the 
apical front of the RPE which is located on the basolateral membrane. Lactic acid is 
eliminated via mono-carboxylate transporter-1 (MCT1) (apical) and mono-carboxylate 
transporter-3 (MCT3) (basolateral). The pH regulation is mandatory for facilitating the 
transport. MCT1 and MCT3 use H+ for the transport and is regulated via apical Na+/H+- 
exchanger and Na+/HCO3- (1:2) co-transporter and basolateral Cl/HCO3- exchanger [124]. 
Through the transport of ions across its epithelial junctions, the RPE regulates the balance 
of ions in the subretinal space. Additionally, to maintain homeostasis, RPE needs to 
compensate for the fast change in ions in the subretinal space [125]. 
K+ ions are the main ion concentration that must be in check. During the dark 
cycle, photoreceptors channels on the POS uptake Na+. The influx is balanced via the 
apical membrane of the membrane of the RPE by releasing K+ ions into the subretinal 
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space. During the light cycle, the cations channels are closed; thus, there is a decrease  
in the outflow of K+ from the inner segment. Also, the Na+/K+-ATPase pump of the POS 
takes up K+. All these events combine to decrease the K+ concentration in the subretinal 
space. RPE K+ channels such as Kir7.1 in the apical membrane release K+ into the 
subretinal space to maintain [K+] concentration [125, 126]. 
The RPE is responsible for the conversion of 11-trans to 11-cis retinal to 
maintain proper visual conduction [129]. First, the trans-retinal is transported through the 
POS from the intradiscal space via an ATP-driven flippase. Trans-retinal is converted to 
N-retinylidinephosphatidylethanolamine by reacting with phosphatidylethanolamine. 
Then retinol-dehydrogenase reduces trans-retinal to trans-retinol in the membrane. Trans-
retinol move to the subretinal space and the interphotoreceptor retinoid-binding protein 
(IRBP) carries the trans-retinol to the RPE. In the RPE, cellular retinol-binding protein 
transfers the trans-retinol to a protein complex. This complex contains three enzymes that 
mediate the conversion of trans-retinol to cis-retinal. Lecithin retinol transferase (LRAT) 
adds an acyl to the retinol. RPE65 (RPE protein with 63 kDa) catalyzes the re-
isomerization of acyl-retinol. And the 11-cis-retinol dehydrogenase oxidizes retinol to 
11-cis retinal. 
Photo-transduction destroys the POS, which is then replenished by the RPE via 
RPE shredding of the damaged part and phagocytosis [130]. This process is regulated by 
the circadian rhythm. It is a daily process that occurrs early in the day and activated by 
light [131]. The phagocytosis mechanism is regulated via three receptors: V5 integrin, 
CD36, and receptor-tyrosine kinase c-mer (MerTK) [132]. The V5 integrin mediates 
the binding of POS to the RPE, MerTK is phosphorylated via focal adhesion kinase 
[133]. That leads to the production of inositol-1, 4, 5-triphosphate leading to an increase 
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in Ca2+ concentration inside the cells, and CD36, thus activating the phagocytosis.  The 
blood-ocular barrier is another factor that plays a crucial role in the homeostasis of the 
retina. 
8 
Figure 1. Schematic of Retinal Layers. The retina function to transmit light from the 
outside world to the brain via the photoreceptors and second-order neurons. The retina 
contains many different layers of cells and synapses, each played a distinct role in 
phototransduction. From the outer layer to the inner layers, OLM, RPE, ONL, OPL, INL, 




Blood Ocular Barrier 
         The blood-ocular barrier (BOB) system is divided into two parts: blood-aqueous 
and blood-retinal barriers. BOB restricts the passage of ions and other blood-borne 
molecules from penetrating the retina through the aqueous humor and the vitreous [43]. 
Breakdown of the BOB allows molecules and other drugs to diffuse to the retina and 
induce inflammation. Another factor that contributes to retinal homeostasis is the 
downregulating immune environment (DIE) in the eye [44]. Degradation of the blood-
retinal barrier (BRB) and loss of the DIE are hallmarks of retinal diseases [45]. The BOB 
system, along with the DIE, is critical in downregulating excessive inflammatory 
response and in maintaining the retinal homeostasis. 
The BOB contributes to the eye being a privilege tissue; thus helping the eye 
abstains from variations in systemic circulations. The BOB maintains an ideal 
environment for the avascular tissues in the eye and regulates the diffusion of chemicals 
into the retina. Because once the molecules pass the ocular barriers, there is nothing that 
can prevent their dissemination to the retina [46]. The blood-aqueous barrier is formed by 
the ciliary body non-pigmented epithelium, Schelemm’s canal endothelium, and the 
endothelium of the Iridal capillaries [47]. Whereas, the BRB consists of tight junctions 
that restricts the movement of molecules in and out of the retina.  
Blood Retinal Barrier 
Blood Retinal Barrier. BRB consists of the inner and outer BRB. The inner BRB (iBRB) 
formed by tight junctions (e.g., Occludin) between the adjacent endothelial cells (ECs), 
and this endothelial layer rests on a basal lamina that is covered by pericytes and glial 
cells (astrocytes, and Müller cells) [48, 49]; whereas the outer BRB is maintained by tight 
junctions between adjacent RPE cells [48, 50]. The BRB functions to control the 
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movement of molecules and fluid into the retina also prevents leakage of macromolecules 
and harmful agents into the retina. 
Endothelial Cells. The endothelial cells (ECs) provide the necessary nutrients and oxygen 
the retina needs to maintain its physiological functions while limiting other blood 
circulating agents from penetrating the retina. ECs mitigate transcellular and paracellular 
transport into the retina. Transcellular transport occurs through diffusion across the lipid 
bilayer for a host of small lipophilic molecules. The other mechanism of transportation is 
through receptor-mediated or constitutive transcytosis. Caveolin-1 contains receptors for 
many substances, including interleukin 1, vascular endothelial growth factor (VEGF), 
albumin, advanced glycation end-products (AGES), and protein kinase C (PKC). 
Vesicular transport under normal conditions is minimal [51]. Tight junctions restricted 
the paracellular traffic.  
Pericytes. In the formation of retinal vasculature, ECs express a very high level of 
platelet-derived growth factor B (PDGF-B). It leads to the recruitment of pericyte cells, 
which then wrap ECs in a 1:1 to ratio. They also form cell-cell contact via Cx43, 
fibronectin adhesion plaques, and N-Cadherin. Pericytes also secrete angiopoietin-1 
which acts via the Tie2 receptor on ECs to promote differentiation, remodeling, and 
maturation. Pericytes also secrete Angiopoietin-2 (Ang-2) which moves together with 
VEGF to promote angiogenesis. Overexpression of Ang-2 causes vascular regression, 
impairs barrier function in part by inducing degradation of TJ (Cadherin). Pericytes also 
secrete transforming growth factor-beta (TGF-) which inhibits migration and 
proliferation of ECs [51]. 
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Junctional Molecules 
ECs form a restricted lining of the vascular wall to regulate the passage of 
substances circulating in the blood and the interstitial space whereas, paracellular limit 
transport via adhesive cell-cell junctional proteins that include gap junction (GP) and 
tight-junction (TJ) [52]. 
Gap Junctions. GJ allowed cell-to-cell communication via hemichannels that are 
consisted of six connexins molecules. Each cell contributes a hemichannel to the 
connection, which opens the plasma membrane of each cell to the other. GJ allowed the 
transfer of small molecules (< 1 kDa) such as ions, glucose, amino acids, and 
neurotransmitters. Most cell types in the retina has GP, including photoreceptors [53], 
endothelial, and pericytes [54]. Connexin-43 (Cx43) is the most prevalent connexin 
molecule in the retina [55]. 
Cx43. Connexin generally localizes in the plasma membrane where it functions in 
intercellular communications via GJ. Cx43 has various phosphorylation sites in its 
carboxy-terminal for protein kinases, e.g., PKC. Cx43 is synthesized as a 40 to 42 kDa 
protein which is then repeatedly phosphorylated through serine residues, and is 
assembled in the trans-Golgi network, and then transported and inserted through the 
plasma membrane. The phosphorylation usually functions in intercellular 
communications via various molecular mechanisms related to assembly, trafficking, and 
closing of the GJ channel [56, 57]. Cx43 hemichannels open during low [Ca2+] 
extracellularly, while PKC can block its opening. 
Tight Junctions: TJ are formed in proximity between two adjacent cells. TJ restrict 
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transports of blood circulating molecules paracellularly. TJ also regulates lipid flip flop 
across the lipid bilayer. They are consisted of more than 40 proteins that are generally 
divided into transmembrane proteins and cytoplasmic scaffolding proteins [51]. 
Occludin: Occludin is a part of the transmembrane class of TJ  proteins and is a 60 kDa 
tetraspan transmembrane component protein with two loops facing the extracellular space 
while both the amino and carboxy-termini in the cytoplasm. The amino terminus 
regulates occludin degradation via interaction with E3-ubiquitin ligase; while the carboxy 
terminus binds to one of the three Zona Occludentes proteins. Occludin functions more in 
regulating barrier properties rather than structural properties between ECs. 
Overexpression of occludin leads to decrease flux into the interstitial space. 
Downregulation of occludin increases paracellular permeability. Occludin knockout mice 
depicted that occludin is not required for barrier formation, but it does play a key role in 
TJ trafficking and stabilization [51]. Occludin and claudins are the two protein/protein 
family that link the ECs together [58]. 
Glia cells and the BRB 
There are three different types of glial cells that populated the retina: Müller 
cells, astrocytes, and microglia. The macroglial cells (Müller and astrocytes) play 
significant roles by maintaining the function(s) of the iBRB.  
Müller Cells. Müller cells are the primary macroglial cells in the retina and constitute 




exchange between the neuronal cells and the blood vessels [59]. They function in 
neurotransmitters recycling, K+ uptake, regulation of blood flow, metabolism control, 
nutrients supply to retinal neurons, anti-oxidative support [60], glycogen storage [61], 
sheath axons [59], and in maintaining the BRB. They can also interact closely with both 
retinal neurons and blood vessels due to their long shape [62]. Docosahexaenoic (DHA) 
protects photoreceptors disk membranes from oxidative damage. DHA also induces 
increased expressions of anti-apoptotic factors via the Bcl-2 family. Müller cells function 
in uptaking and delivering DHA to photoreceptors [59]. The depletion of Müller cells 
leads to the breakdown of the BRB [61]. These cells secreted anti-angiogenic factors to 
maintain pro and anti-angiogenic environment and thus BRB health.  
  
Astrocytes. Astrocytes are non-prominent in avascularized area, generally located within 
the NFL.  They are wrapped around blood vessels. Astrocytes primarily communicates 
via GJ [59]. Astrocytes are the primary producer of VEGF and thus play a key role in 
neovascularization. Other physiological functions of astrocytes include mechanical 
support for axons, neurotrophic support, and maintenance of the BRB. Astrocytes 
contained aquaporin4 channels within their plasma membrane which help regulate the 









Figure 2. A Brief Schematic of the iBRB. iBRB consists of TJ between adjacent ECs 
that are covered by pericytes. The capillary cells are wrapped by glial cells (astrocytes, 
and Müller cells). Although pericytes and glial cells are critical to the iBRB function, the 





Downregulatory Immune Environment (DIE). The immune-privileged status of the eye is 
maintained by the BOB and DIE. Transportation of antigens and tissue drainage occurred 
via the blood route instead of the lymphatic pathway [63]. The inflammatory response in 
the eyes is particular to the eye. To protect the physiological functions, the eye regulates 
immune response strictly and manages its inflammation. The retina and choroid contain 
many immune cells that include choroidal macrophages, microglia, dendritic cells, and 
the mast cells population [64]. These cells introduce antigen to T cells and produce 
cytokines to non-specific stimuli such as bacterial liposaccharides (LPS). The presence of 
antigen-non-specific inflammation can be disastrous to host tissue. The BRB protects the 
retina from the aqueous chamber, and the vitreous body via immunosuppressive 
functions. Many factors played a crucial roles in maintaining the DIE state in the eye, 
including Müller cells, RPE, and the microglia. The normal retina has low major 
histocompatibility complex (MHC) molecules and there is an absence of the bone 
marrow-derived cells that function with tissues as Antigen Presenting Cells (APCs). 
Anterior Chamber Associated Immune Deviation (ACAID). ACAID is the most studied 
immune privilege mechanism in the eye. It is unique to the anterior chamber, but there is 
evidence that the same mechanism exists in the vitreous and the subretinal space as well 
[65]. It contains TGF- which is capable of reprogramming the APCs to produce less IL-
2, less amount of CD-40 in the microenvironment of the eye, and also help produce more 
TGF- which suppresses T cell activation [46]. 
BRB and DR. DR is commonly defined as degeneration and occlusion of the 
microvessels, which caused fluid accumulation and abnormal neovascularization in the 
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retina [66]. Loss of pericytes in retinal capillaries is one of the factors that leads to iBRB 
breakdown [67]. Hyperglycemia (HgA) causes retinal hypoxia and vasodilation increases 
retinal blood flow in response to the hypoxia temporarily. Exhaustion of autoregulation 
causes apoptosis of retinal capillary pericytes. The death of pericytes disrupts pericytes-
endothelial complex which then leads to an impairment in the endothelial TJ function. 
These events together caused the breakdown of the iBRB. 
Retinal ECs in the iBRB are potential targets of the inflammatory markers such 
as eicosanoids, cytokines, and the growth factors. Chronic HgA upregulates 
inflammatory mediators which in turn induces leukocytes adhesion to ECs which further 
injures the iBRB [68-70]. Breakdown of the iBRB as a result of cytokines release 
generate an inflammatory response which further increases the release of the 
inflammatory mediators, thus additionally exacerbating the situation. Leukocytes 
adhesion also induced retinal hypoxia, the retinal hypoxia also leads to abnormal blood 
vessel growth concurrently [71, 72]. 
Diabetic Retinopathy 
The earliest sign of DR is a dysfunctional iBRB. DR is characterized by loss of 
pericytes [73, 74], basement membrane thickening, microaneurysms [75], acellular 
capillary, and iBRB breakdown. The factors that contribute to capillaries degeneration 
are occlusion of the capillary’s lumen by white blood cells or platelets, and death of 
capillaries cells due to hyperglycemia. There are many biochemical mechanisms 
proposed for the pathogenesis of DR, although the etiology is yet to be precise. Chronic 
HgA is the main factor contributing to the development of DR, and its complications. The 
earliest retinal changes due to HgA are biochemical, cellular, or hemodynamic in nature. 
Metabolic deregulation affects 
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the neurons and the support cells of the retina. However, it is the microvessels that in fact 
are affected the most. They [capillaries] dominate clinical events of the disease and are 
also the focal point for the development of macular edema and neovascularization. In the 
early stages of DR, functional cells of the retina exhibit changes such as glial cell 
reactivity, alterations in glutamate metabolism, and neuronal cell death [76-78]. Until the 
development of retinopathy, vision is normal in diabetics patients if they don’t have any 
other concurrent eye problems. DR is divided into two stages: Non-proliferative DR 
(NPDR) and Proliferative DR (PDR). After five years of living with diabetes, NPDR 
symptoms start to appear. NPDR is intraretinal microvascular derangement that could 
progress to diabetic macular edema (DME) (accumulation of fluid in the macula) or PDR 
(extraretinal neovascularization). Progressive retinal ischemia and the rise in local growth 
factors are the primary mechanisms outlined in the development of PDR. PDR is new 
growth of blood vessels in the retina or optic disc that extends along the retinal surface or 
into the vitreous cavity [79, 80]. Pathogenesis of PDR involved hypoxia that results in 
low perfusion of retinal tissue, thus prompting neovascularization (directly related to 
VEGF). Initially, the new blood vessels are barely visible, then they gradually increase in 
size, and could become as large as a retinal vein. New blood vessels are usually 
asymptomatic [81, 82]. The new growth of blood vessels is gradually accompanied by 
fibrous proliferation, and it is this contraction of the fibrous tissue that can can lead to 
retinal detachment and vitreous hemorrhage. These two traits more often than not lead to 
vision loss in PDR. 
The cornerstone of NPDR treatment is glycemic control while managing PDR 
has the following aims: decrease the growth of blood vessels, contraction of vitreous, and 
fibrovascular proliferation. Photocoagulation is the gold standard for PDR treatment. 
However, photocoagulation comes with complications since high density/intensity laser 
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may cause loss of night and colored vision [83] and reduced contrast sensitivity [84]. 
Other treatments for PDR include VEGF Inhibitors and Vitrectomy [85]. 
Many biochemical mechanisms have been put forward to explain the vascular 
pathology of DR. Among the proposed pathways are aldose reductase (AR), AGEs 
formation, reactive oxygen intermediates elevation, PKC, and the inflammation. 
DR-Biomolecular Mechanisms 
AR Pathway. Retinal capillary cells (endothelial, and pericytes), and glial cells expressed 
AR and thus are subjected to the polyol pathway [86]. The polyol pathway or the AR 
pathway is induced during high blood glucose levels [87]. First, AR reduces glucose into 
sorbitol (nicotinamide adenine dinucleotide phosphate hydrogen; NADPH serves as a 
cofactor). Next, sorbitol dehydrogenase (SD) reduces into fructose (nicotinamide adenine 
dinucleotide (NAD+) serves as a cofactor). Since sorbitol cannot cross across the cell 
membrane it accumulates intracellularly inducing an osmolality effect [87]. Next, as the 
substrates use NADPH and NAD+ in this pathway, they are quickly depleted thus 
decreasing the body’s capacity in responding to the OS. For example, the use of NADPH 
hinders its bioavailability for glutathione reductase [88]. NADH/NAD+ ratio is increased 
due to the use of NAD+ by SD. Further, NADH oxidase could also use NADH as a 
substrate to increase the generation of ROS [89]. Additionally, fructose can further 
metabolize into fructose-3-phosphate, and 3-deoxyglucosone, both of which can become 
the glycosylating agents [90, 91]. This pathway generates osmolality effects, glycating 
agents, and OS. Studies have shown that inhibition of AR in diabetic animal models 
prevents retinal injuries [92]. Although clinical trials with AR inhibitor have not been 
significantly fruitful [93]. 
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AGEs. Amine group modification of a protein by reducing sugars such as glyoxal, 3- 
deoxyglucosone, and methylglyoxal, generate AGEs [94]. Retinal levels of AGEs 
increase in diabetic’s rat model and humans [95]. The presence of AGEs on the basement 
membrane interferes with pericytes and ECs communication. AGEs bind to their 
receptors, activate NF-B, and generate ROS. 
PKC: PKC is a serine/threonine-protein kinase that mediates many cellular signal 
transduction pathways [96]. The various isoforms of PKC are activated via diacylglycerol 
(DAG), calcium, and other substrates. HgA increases the expression level of DAG [97]. 
Studies reported that DAG levels have increase in the retina of the diabetics [98]. 
Activation of PKC increases albumin permeability across ECs [99, 100] and hinders 
vasodilation via depleting nitric oxide (NO) levels. PKC also caused the loss of pericytes 
[101]. 
OS: The retina is perfused 300 times more than both the heart and the cerebral cortex, 
thus making it more susceptible to OS; phototransduction, and shedding of POS by the 
RPE also contribute. ROS, free radicals in the form of hydroxyl radicals, and superoxide 
anion are very reactive, mainly due to the unpaired electrons in their valence shell [102]. 
Many factors lead to the generation of ROS including the mitochondria electron transport 
chain [103]. Under normal conditions, the mitochondria contribute the most to ROS 
levels.  The process of aging, and inflammation can disrupt homeostasis by generating 
more ROS than the body can remove thus inducing the process called OS [104, 105]. The 
body uses antioxidant (vitamin C and E, superoxide dismutase; SOD, and catalase) to 
neutralize ROS [102]. Once the body anti-oxidant system is overloard that create OS. 




Increased ROS injure ECs, activate NF- [107-110], and recruit neutrophils [111].  
There is evidence that OS is the main factor that triggers the chronic inflammation 
response in the retina [112]. Inflammation increases expression of inflammatory 
mediators, promotes leukocyte adhesion to retinal capillary walls, and occludes retinal 
capillaries causing hypoxia. Eventually, breakdown of the iBRB happens.  
 
 Inflammation 
Basics Concept in Immunology. Immune privilege of the eye is maintained by the BOB, 
DIE, and the lack of direct lymphatic drainage from the eye [113]. The immune system 
consists of two parts: innate and adaptive. The innate immune pathway is immediate and 
nonspecific. Pattern recognition receptors (PRR) recognizes the conserved microbial 
patterns and triggered a nonspecific inflammatory reaction; for instance, toll-like 
receptors (TLR) recognize LPS of the gram-negative bacterial outer membrane [114]  
which activate immune cells, monocytes, macrophages, natural killer (NK) cells, 
polymorphonuclear cells, eosinophils, and basophils. The adaptive immune response, 
however, is more complicated and elaborated below.  
 
Adaptive Immunity. The key components include B and T lymphocytes, which contain  
receptors (immunoglobulins; Igs) for recognizing antigenic epitopes [115]. Igs are 
expressed by B cells and T cells in the absence of exogenous stimulation. Igs contains 
unique configurations that recognize specific antigens. Each group of lymphocytes 
depicts the same cell surface receptors to identify multiple epitopes, and to accomplish 
this billions of lymphocytes are generated.  
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Figure 3. Mechanism of Diabetic Retinopathy Pathology. Hyperglycemia during 
diabetes activates many pathways such as PKC, AGEs, and polyol. These pathways 
induce oxidative stress, and inflammation in the retina. Inflammation contributes to 
retinal vascular occlusion, and dysfunction of retinal capillary cells that lead to the 





After maturation in the thymus (T cells) or bone marrow (B cells), lymphocytes 
remain in the dormant or G0 phase of the cell cycle until an antigen binds to its receptor 
(called naïve). Molecule binding to a B or T cells triggers an immune response to destroy 
the bound molecule or the antigens. If the molecule is pathogen-derived then it leads to 
the destruction of the pathogen. If it is a cell-derived then it leads to autoimmunity, and 
therefore occurrence of the tissue injury. 
Activation of a naïve lymphocyte leads to the proliferation of that lymphocyte 
which recognizes a specific epitope. T cells (CD4+ and CD8+) become cytotoxic once 
activated or differentiate into effector cells. CD8+ T cells become cytotoxic once 
activated. CD4+ T cells via interleukins (IL) differentiate into one of three effector T cells 
(Th1, Th2, and Th17). IL-4 leads to Th2,  IL-12 leads to Th1 [116], whereas IL-1 and IL-
23 lead to Th17 differentiation [117]. Th1 and Th2 cells become memory cells that 
trigger the immune response if the antigens reappear. Th1 secretes cytokines that target 
macrophages, and other cells involved in the immune response. Th2 stimulates B cells 
proliferation to produce antibodies to kill the invader. Th17 cells produce IL-17 [118], 
and IL-23 to fight fungal and bacterial infections. 
 The adaptive immune response is divided into three parts: antigens recognition, 
transportation, and presentation to lymphocytes. Antigens are recognized, processed, and 
presented (through MHC) to lymphocytes by dendritic cells, and macrophages. There are 
differences in the process of antigen presentation. B cells can engage with naïve antigen 
directly but T cell receptor (TCR) can only recognize peptide fragments presented with 
MHC molecules (Class I or II). MHC Class I molecules (expressed in most cells) present 
peptides derived from protein degradation in the cytoplasm (intracellular antigens). MHC 
Class II molecules (expressed  in APCs and lymphocytes) present peptides derived from 




lymphocytes activation [119]. APCs upregulates CD80, CD86, ICAM-1, and CD40 
molecules to function as ligands for lymphocytes receptors. APCs also secrete soluble 
cytokines such as IL-12, IL-6, IL-10, and IL-1 to stimulate lymphocytes further.   
                CD4+ T-cell activation leads to CD4+ proliferation and cytokines secretion such 
as IL-2, IL-3, granulocyte-macrophage colony-stimulating factor, interferon-gamma 
(IFN-), and IL-4 which serves as growth and stimulation factors for lymphocytes and 
APCs. IL-2, IFN-, and IL-4 promote differentiation of CD8+ T lymphocytes to mature 
cytotoxic T lymphocytes. Cytokine production by CD4+ T cells also promotes activation 
and differentiation of B lymphocytes. IL-2, and IFN- stimulate B cell to produce 
immunoglobulin g (IgG) while IL-4, 5, 6, and 10 stimulate the production of IgG, IgE, 
and IgA antibodies.  
              Final products of processing in the lymphoid tissues are activated effector CD4+, 
CD8+, and B cells. These cells travel through the blood to execute the response. Activated 
B cells secrete antigen-specific antibodies to kill the target directly. Activated CD4+ T 
cells secrete cytokines, and IFN-, which in turn recruit the cells of the innate immune 
system to the site of the antigen. Activated CD8+ lyse target cells and produce 
proinflammatory cytokines, especially IFN-. Cytokines involved in the response 
perpetuate a positive feedback loop at the target sites. Blood vessels become leaky, 
vascular endothelial cells display ligands that bind to immune cells receptors, and 
chemokines secreted by local inflammatory cells to attract more immune effector cells 
and the cascade continues [119].  
 
Inflammation in DR 
DR is regarded as an inflammatory disease due to the presence of inflammatory  
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mediators that are found in the vitreous and the retina of diabetic animals models and the 
patients. The increase in expression of these markers is associated with a dysregulation in 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-) [120]. 
NFKB. NF- is a family of five transcription factors that has structurally related 
subunits: NF- 1 (p50), NF- 2 (p52), RelA (p65), RelB, and c-Rel. Once activated, 
they form either hetero or homodimers and get translocated into the nucleus. In the 
nucleus, they bind to  DNA binding sites and increase the expression of  NF- 
targeted genes [121]. 
NF- regulates gene transcription that plays key roles in inflammation, immune 
cell development, cell cycle, proliferation, and cell death [122, 123]. NF- is pertinent 
for both innate and adaptive immune cell functions. It regulates survival, activation, and 
differentiation of both innate and adaptive immune systems cells. NF- activation 
induces expressions of pro-inflammatory genes, cytokines, chemokines, 
immunoreceptors, apoptosis, proliferation, and inflammasome [120]. 
Stimuli that activate NF- include TLRs, antigen receptors, OS markers, 
genotoxic stress, cytokine, and growth factors. There are two types of NF- activation: 
specific and non-specific. Both are influential in regulating inflammation and immune 
response [124]. The NF-  subunits reside in the cytoplasm where they remain inactive 
via inhibitory proteins of the I (IB) family [125]. Activation of NF-B requires IB 
kinase (e.g., IKK) to phosphorylate the IB which then is recognized by the E3 ligase 
to degrade the inhibitor. This process induces the translocation of NF- heterodimers 
(e.g., p50/RelA) into the nucleus [126-128], where they bind to DNA sequences known 
as  sites [121]. 
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Figure 4: Immune System Mechanism. The immune system consists of two parts: 
innate and adaptive. The innate system is the primitive and nonspecific one and uses 
dendritic cells, monocytes, macrophages, and other immune cells to destroy the invading 
pathogen(s). On the other hand, the adaptative system uses the bone marrow-derived (B 
cells) and thymus-derived Treg cells, innate immune cells, antibodies, and immune 




In contrast, the non-specific pathway responds to a specific set of stimuli, such as 
receptor-activated nuclear factor kappa B (RANK) [129, 130]. The subunits activated in 
this pathway are RelB and p52 and require IKK and cleavage of p100 to p52. First, 
processing of NF- 2 (p100) occurs [129] followed by translocation of p52/RelB into 
the nucleus [129, 131]. The specific pathway is involved in all aspects of the immune 
system, and the non-specific is complementary to the adaptive immune system regulation 
[130]. NF- is regulated primarily via a negative feedback loop wherein activation of 
NF- induces production of IB [132]. Activation of NF- mainly heterodimerizes 
into p50-p65 thus transcribing the pro-inflammatory proteins (iNOS, ICAM-1) [133]. 
Inflammation serves as a protective mechanism against tissue damages and 
infections under physiological conditions, however it may be detrimental in the long 
term. Deregulation of inflammatory responses causes damages to host tissues that could 
lead to the development of short or long-term inflammatory diseases. Chronic 
inflammatory conditions such as diabetes involve deregulation of NF- activation. 
Dysregulation of NF-  induces an excessive increase in inflammatory proteins. Recent 
studies have shown an increase in inflammatory mediators such as COX-2, and iNOS in 
the retina and vitreous of DR animal models and the patients, as stated earlier. These 
molecules are consistent with the innate immune pathway. Also, other studies have also 
shown that retinal inflammation is also associated with the activation of NF- [134]. 
iNOS. Inducible Nitric Oxide Synthase (iNOS) meditates NO production from L-
arginine. Regular production of NO is generated via two NO synthases (neuronal and 
endothelial). While iNOS generation of NO involves solely in inflammation. An elevated 
level of NO is associated with many inflammatory diseases, e.g., inflammatory bowel 
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disease [135-137]. iNOS has high expression in activated immune cells and low to no 
expression in most resting cells [135]. Activated NF- induces transcription of iNOS 
[120]. Studies in the literature shows an increased iNOS levels in the retina of diabetic 
animals, which associated with apoptosis of retinal cells, leukostasis, and iBRB 
breakdown [138]. iNOS elevation is very well present in the retina of human patients 
[139-142]. iNOS has also been shown to mediate the production of oxygen radicals. 
iNOS generates superoxide anions in macrophages [143]. NO could react with 
superoxide anion to form peroxynitrite, and injure macromolecules inside the cells. 
Increase production of NO could also result in nitration and nitrosylation of the retinal 
proteins, which is also toxic. NO elevation generated by iNOS causes the loss of 
pericytes, and retinal thinning (GCL, IPL, and OPL). Studies of retinal cells exposed to 
high glucose (HG) demonstrated that NO (particularly iNOS generated) regulates 
prostaglandin E2 (inflammatory marker generated by COX-2) expressions. iNOS is also 
associated with GCs loss in Akita mice after 22 weeks of diabetes [144]. Inhibitor of 
iNOS (aminoguanidine) has shown to decrease vascular injuries associated with DR in 
rodents [145-147]. Studies of retinal cells exposed to HG demonstrated that NO 
(particularly iNOS generated) increases the expression of cyclooxygenases-2 (COX-2) 
[144]. 
COX-2. Eicosanoids are signaling molecules that are derived from arachidonic acids such 
as prostaglandin (PG), thromboxane, and leukotrienes. Cyclooxygenase enzymes mediate 
the first two steps of eicosanoids synthesis. Many isoforms have been identified, such as 
COX-1, and COX-2. COX-1 is expressed in most tissues and it functions to maintain PG 
production. PG is known to regulate renal blood flow, immune responses, and 




[154], corneal neovascularization [155], corneal edema [156], retinal blood flow [157],  
iBRB, and BOB impairment [158].  
COX-1 maintains physiological productions of eicosanoids, whereas COX-2 
eicosanoid production occurs in the presence of inflammation. COX-2 is generally absent 
from most tissues, but its expression is increased in the presence of bacterial LPS and 
proinflammatory cytokines; thus, COX-2 has high expression in immune cells 
(monocytes, macrophages, and ECs) [159]. NF- activation upregulates COX-2 gene 
expression in retinal cells [160]; and is associated with iBRB breakdown [161]. 
Interestingly, COX-2 expression is elevated in the retina of Akita mice [162]. Another 
inflammatory mediator that is positively regulated by NF- and has high expressions in 
the retina of DR is the intercellular adhesion molecule-1 (ICAM-1).  
 
ICAM-1. ICAM-1 is a membrane-bound glycoprotein and serve an important function in 
immune responses, e.g., leukocyte trafficking [163]. ICAM-1 is consisted of five Ig 
domains, a transmembrane domain, and a linker in the cytoplasm that interacts with actin 
molecules [164]. It is expressed in ECs, leukocytes, platelets, epithelial cells, and glial 
cells. Its expression is low when inflammation is not present. It performs functions in 
immune cells such as adhesion, migration, and aggregation [165]. Leukocytes adhesions 
(leukostasis) to retinal endothelium is associated with iBRB breakdown [166].  
Leukostasis is elevated in the retina during hyperglycemic conditions [166]. 
Leukostasis in retinal vessels is mediated by elevation of ICAM-1. Activation of NF- 
increases ICAM-1 expression [167]. Leukostasis elevation is linked with an increase in 
vascular permeability [168]. Inhibition of ICAM-1 reduces leakage and leukocytes 
adhesion in the retina of diabetic rats [169].  
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Leukostasis in retinal vessels is mediated by elevation in ICAM-1 and CD18 
leucocytes integrin [170]. Streptozotocin (STZ) induced diabetes in mice that are 
deficient in ICAM-1 shown less leukostasis in retinal vessels [171]. STZ induced WT 
C57BL/6 J mice exhibited increased expression of ICAM-1 in their retina [169]. 
Activated leucocytes injected into the retina of healthy mice show increased leukostasis 
via ICAM-1 [172] and inhibition of ICAM-1 decreases leukostasis in the retina of 
diabetic rats [173]. 
Pyroptosis 
Pyroptosis is a cell death pathway due to inflammation. It involves the assembly 
of an inflammasome, activation of caspase 1 (Casp-1), IL-1 and IL-18. Pathogen-
associated molecular patterns (PAMPs) and danger-associated molecular patterns 
(DAMPs) induce inflammasome assembly [174]. Inflammasome contains a nod-like 
receptors protein (NLRP) family receptors (e.g., NLRP3), adaptor protein ASC 
(apoptosis-associated spec-like protein containing CARD) and pro-caspase 1. 
Inflammasome plays a vital role in the innate immune system against infections, but its 
deregulation could lead to the development of autoimmune and inflammatory diseases 
also [175]. NF- regulate inflammasome assembly [175]. NF- is a known activator 
of nod-like receptor pyrin domain 3 (NLRP3) [176, 177]. NF- induces pyroptosis 
through activation of NLRP3 [178]. 
NLRP3. Nod-like receptors (NLRs) are PRR and generally located in the cytoplasm, thus 
making it possible to detect pathogenic invaders inside the cell [179]. Most NLRs are 
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Figure 5. Nuclear Factor Kappa B Activation. NF-  homo/heterodimerizes and 
translocate into the nucleus once activated. They bind to B DNA binding sites and 






active during the innate immune responses, and are activated via PAMPs, DAMPs, cell  
stress, or ROS. NLRs family have 14 distinct members, named NLRP1 to NLRP14 [180]. 
NLRP3 can also be activated by extracellular ATP, and UVB radiation [180]. NLRs form 
complexes known as inflammasomes, which cleave casp-1, and casp-1 cleaves 
interleukins-1 beta (IL-1), and interleukins 18 (IL-18) [181]. NLRP3 is the most studied 
NLRs and various stimuli could trigger its activation. It is involved in multiple 
pathologies, e.g., type II diabetes, and obesity [182]. NLRP3 structure has three distinct 
domains:  pyrin domain (PYD), leucine-rich repeat (LRR) domain, and a nucleotide-
binding domain (NBD) [183]. NLRP3 inflammasome is consisted of NLRP3, ASC, and 
Casp-1. Stimuli activate NLRP3 via interaction with the LRR, then the PYD and the 
NBD are free to interact with other entities. Through the NBD domain, NLRP3 
oligomerizes and then recruit ASC to form the NLRP3-ASC complex [184]. ASC then 
recruits casp-1, casp-1 auto processed, and cleaved pro-IL-1 to IL-1 and IL-18 [185, 
186]. The NLRP3 activation mechanism is yet to be defined though. A common 
mechanism has been suggested that the extracellular ATP stimulates purinergic P2X7 
ATP-gated ion channel leading to the efflux of K+ ions. Pannexin-1 membrane pore 
protein is recruited into the target cell and that can lead to the activation of the assembly 
of the NLRP3 inflammasome [180].  
HgA can upregulate NLRP3 expression in cultured Müller cells [180]. The role 
NLRP3 and inflammasomes play in DR is still under intense investigation. Hui Chen et 
al. reported a high level of NLRP3 expression in the blood from diabetic patients. They 
speculated that its activation could be due to elevation in ROS that could presumably be a 
byproduct of other molecular mechanisms, e.g., polyol pathway [187]. 
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Casp-1. Casp-1 is part of the caspase family of cysteine proteases that involve either (a) 
an increase activation of proinflammatory cytokines or (b) cellular death by apoptosis. 
However, casp-1 can participate in both cytokines activation and apoptotic cell death. 
Casp-1 resides in the cytoplasm until activation by NLRP3, and then it heterodimerizes 
into two subunits (10 & 20 kDa) [180]. Casp-1 activation induces expression of both IL-
1 and IL-18 [188]. HgA has been shown to activate casp-1 in the retina of diabetic mice, 
patients, and Müller cells [188]. Inhibition of casp-1 by minocycline prevents the 
degeneration of retinal capillaries cells induced by the development of diabetes [188]. 
Casp-1 activation induces expression of both IL-1 and IL-18 [188]. 
IL-1 IL-1 is part of the IL-1 family which is consisted of 11 different ligands and 
receptors. These ligands function to induce inflammation or anti-inflammation 
independently in the blood or tissues. IL-1 is one of the first ILs discovered. IL-1 is 
synthesized as pro- IL-1 , which remains inactive until it is cleaved via casp-1 to 
produce mature IL-1 [180] IL-1 binds to its receptor (IL-1 receptor type 1; IL-1R). IL-
1 action is regulated via IL-1R antagonist, which competes for the same receptor. IL-
1 functions in the extracellular milieu where it resides within the cytosol and is secreted 
upon stimulation or cell death. Many different retinal cells produced IL-1 including 
microglia, and the astrocytes [189]. IL-1 played a crucial role in innate immune 
response, helps fighting pathogens, and tissue repair. IL-1 induces the activation of 
microglia and other retinal glial cells along with proinflammatory mediators. Thus, 
prolonged exposure or overexpression of IL-1 can lead to tissue damage. Elevation of 
IL-1 expression was reported in the retina of diabetic rodents experimental models as 
early as eight weeks after the onset of HgA. IL-1 has also been reported in the 
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vitreous of patients with DR. IL-1 administration in the vitreous of nondiabetic rats led 
to apoptosis of retinal capillary cells via activation of NF-B [189, 190]. Susana Vallejo 
et. al reported that anakinra (inhibitor of IL-1R) prevented impairment of ECs in STZ 
induced diabetic rats via NF-B activation and subsequent increase in iNOS production 
[191]. Literature also reported that constant exposure to IL-1 led to ECs impairments 
and degeneration of blood vessels [188]. Other studies reported that HG increased the 
expression of IL-1 in Müller cells [192]. In the retina of diabetic mice, casp-1 and IL-1 
have been detected as well [193]. These markers have also been shown to be implicated 
in the death of microglia and Müller cells [194]. Furthermore, IL-1 increases the 
expression of COX-2 and adhesion molecules in ECs [180]. 
iBRB and DR 
  Recent studies reported existence of reduced gap junction intercellular 
communication (GJIC) thus highlighting the iBRB dysfunction. Cx43 expression in 
numerous retinal cells is downregulated during HG environment [195]. Studies have 
shown that HG downregulates Cx43 expression levels in the mitochondria, potentially 
promoting endothelial and pericytes cell death [196, 197]. HgA showed to impair Cx43 
expression, thus decreasing the activity of GJ, and the decrease in expression of the TJ 
molecules in ECs, and a subsequent cell death phenotype [55]. 
Studies in astrocytes depicted that activation of NF-B by TLR-3 protein leads to 
a decrease in the expression of Cx43, thus reducing GJIC [198]. Kunihiko Nagasawa et 
al. reported that Cx43 is associated with TJ proteins in the blood-brain barrier (BBB) 
[199]. Studies in rat retinal ECs depicted that HG decreased Cx43 expression, and this 
decrease in Cx43 expression downregulated TJ protein, particularly occludin, thus 
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impairing cell permeability but the mechanism(s) is yet to be discovered [200]. 
HgA decreases expression and redistribution of occludin [58, 201]. Ermelindo 
Leal et al. found that increased expression of NO generated by iNOS reduced the 
expression level of occludin in STZ induced diabetic rats, therefore leading to the 
breakdown of the iBRB [201]. NF-B activation induced by TNF- can internalize 
occludin which may disrupts the TJ barrier between epithelial cells in inflammatory 
bowel disease [202]. 
Loss of pericytes occurs during HgA in part due to a reduction in PDGF-B levels. 
Additionally, a concomitant loss of both the pericytes and ECs could result in acellular 
capillaries (no ECs or pericytes). This particular aspect increases the likelihood of 
microaneurysm formation and bleeding in the retina which would indicate iBRB 
breakdown. In the presence of IL-1, activated pericytes secrete various cytokines and 
chemokines, including IL-1. It secretes these factors to attract immune cells to the sites 
of inflammation. Pericytes increase the expression of ICAM-1, other adhesion molecules, 
and at the same time downregulate the TJ molecules [203] thus facilitating immune cell 
passage through the endothelium. 
HG leads to the death of Müller cells via activation of casp-1 and IL-1 . 
HgA increased the expression of IL-1 in Müller cells [61] and its secretion. IL-1 then 
bound to IL-R1 on ECs and increased the expression of ICAM-1 [60]. Studies have 
shown that HgA impaired Müller cells uptake of glutamate, which could lead to 
glutamate toxicity in diabetic rats. HgA also reduced potassium uptake, further 
exacerbating the glutamate toxicity by increasing the neuronal excitation [61]. Diabetes 
impairs Müller cells function via decreasing expression of glutamine synthase, and the 
activity of the glutamate transporters [204]. Selective ablation of Müller cells 
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results in BRB in Rlbp-LacZ mice which also impairs the A-wave and B-wave responses 
of the mice [204]. HgA significantly impaired communication between astrocytes by 
reducing Cx43 expressions and other GJ as early as four weeks post STZ treatment in 
rats. These animals also depicted the death of astrocytes after six weeks of HgA [205]. 
Inflammation and Intraocular Pressure 
The aqueous humor is secreted by the ciliary body (CB) epithelium and it is the 
key factor that determines the dynamics of intraocular pressure (IOP). It is the plasma 
components of the CB that help secrete the aqueous humor into the posterior chamber 
(PC) which then circulate into the anterior chamber (AC). From there the aqueous humor 
drains into the trabecular meshwork and Schlemm’s canal. The cells in the CB 
synthesized the aqueous humor in three steps. First, when the blood flows through the CB 
the plasma in form an ultrafiltrate is made due to the pressure gradient between blood 
flow and the interstitial of the ciliary body. Last, the epithelium of the CB transports the 
aqueous humor from its basal end to its apical surface actively (and selectively) and then 
pumping it into the PC. Systemic blood pressure has very little to do with aqueous humor 
synthesis, although the first step has to do with blood flow, only about 4% of plasma is 
being filtered [206]. 
Circulation of the aqueous humor generates the IOP within the AC. IOP plays a 
crucial role in the pathophysiology of glaucoma. An increase in IOP is a key risk factor 
for glaucoma, although some patients with normal IOP may have glaucoma, while others 
with high IOP may not have glaucoma. One factor that is associated with an increase in 
IOP is increased resistance in outflow [206]. 
HgA and IOP. Multiple demographics studies concluded that there is an increase 
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in IOP in diabetic patients than nondiabetic patients, and that an increase in IOP is 
independent of open-angle glaucoma. The mechanism has not yet been determined 
though. It is speculated that HgA causes an osmotic gradient that shifts fluid between 
plasma and intraocular fluids thus elevating the IOP [207]. A Japanese study found a 
significant correlation with IOP and HBA1c levels in patients with DR [207]. Similarly, a 
Chinese population study found an association between DM with high IOP (>21 mmHg) 
[208]. Demographic study in Singapore also found an association between elevated IOP 
and DM. Even after accounting for the difference in central corneal thickness, which is 
higher in diabetics individuals, the increase in IOP was independent of the development 
of glaucoma. 
JSH-23 Mechanism 
4-methyl-N1-(3-phenyl propyl)-1, 2-benzenediamine (JSH-23) is a selective 
inhibitor of NF--p65/p50. It stops nuclear translocation of NF--p65/p50 and thus 
helps stop the transcription of its target genes [209]. JSH-23 has an IC50 of 7.1 M for 
NF-B nuclear translocation and transcriptional activity on macrophages RAW 264.7 
stimulated by LPS. Kumar et al. showed that oral administration JSH-23 inhibits NF-B 
in STZ induced male Sprague Dawley rats, and was able to decrease the expression of 
COX-2, iNOS in the sciatic nerve and improve nerve function [210]. When JSH-23 was 
used in a chronic mild stress model to inhibit the effect of NF-B, it was able to decrease 
inflammatory mediators and increase anti-oxidant defense in the hippocampus [211]. 
After sepsis, LPS induced cardiac injury through differentiation of M1 macrophages. 
JSH-23 inhibits LPS induced cardiac injury in a sepsis animal model [212]. Transition 
metal ions activate NF-B and NLRP3 in bone marrow-derived macrophages, thus 
42 
pyroptosis and again JSH-23 was shown to inhibit NLRP3 activation via inhibiting 
phosphorylation of NF-B in macrophages after transition metal activation [213]. 
Cisplatin activates NF-B and induces acute kidney injury by necrosis and apoptosis of 
proximal tubular epithelial cells. JSH-23 reduced many of the response genes of the NF-
B activation, including casp-1 in C57BL6J mice treated with cisplatin [214]. To our 
knowledge, JSH-23 has not yet been used to decrease NF-B activation in DR or Akita 
Mice. Therefore, to test our hypothesis, we used the Ins2Akita mouse (Akita) that has been 
well-characterized as an excellent model system to study T1D. Akita harbors a missense 
mutation in the Insulin 2 gene, which leads to a conformational change in insulin protein, 
causing it to accumulate in pancreatic β-cells. Accumulation causes loss of cellular 
function, decreased cell density, and, finally, cell-death leading to HgA because of insulin 
deficiency [144, 215-217]. These mice become hyperglycemic after four weeks of age. 
HgA-induced retinal pathology ensues after 12 weeks, starting with appearance of 
acellular capillaries, and infiltration of the leukocytes into vascular walls [144, 218, 219], 
increased in vascular permeability, degeneration of astrocytes and microglia, thinning of 
the IPL, INL, and loss of RGCs [219]. The Akita model has many vital advantages. It has 
an autosomal dominant mutation with stable hypoinsulinemia, and lacks systemic 
immunologic alterations. It is fertile, and its background does not contain the rd (pde6) 
variations; such modification are responsible for photoreceptors degeneration [144]. 
Summary. HgA in Type I Diabetes (T1D) induces retinal inflammation via NF-B 
activation. Retinal capillary cells such as endothelial, pericytes, and glial cells are critical 
parts of the iBRB but remain potential targets of inflammatory mediators. Inflammatory 
mediators also targeted junctional molecules thus impairing the cell-cell 
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communication and the paracellular transport. NF-B increased the pro-inflammatory 
genes, which induced iBRB breakdown. Thus, we proposed that the inhibition of NF-B 
p65 subunit with JSH-23 to prevent retinal microvascular impairment in the retina of 
Akita mice. 
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Figure 6. Molecular Structure of JSH-23. JSH-23 inhibits the nuclear translocation of 




Figure 7. Summary.  iBRB is consisted of endothelial, pericytes, and glial cells. The 
ECs and their TJ regulate transcellular and paracellular transport into the retina. HgA 
activates NF-B, which then increases the expression of inflammatory mediators thus 
causing leukostasis, vascular occlusion, and the iBRB breakdown. 
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FIGURE 7         
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Figure 8. Summary of Background. HgA (in T1D Akita mouse model) dysregulates NF-B. 
NF-B overexpression increases the production of pro-inflammatory molecules from its target  
genes that lead to degradation of the junctional molecules in the affected retinae. As a result, the 






HYPOTHESIS AND SPECIFIC AIMS 
Key Objective 
The goal of this study is to determine the effects of chronic inflammation in 
impairing retinal capillary vessel in Akita (T1D model) and to investigate whether JSH-
23 can inhibit these injuries. 
Hypothesis 
During Diabetes (T1D), vision loss is due to retinal vascular leakage by an 
increase in inflammatory mediators (NF- p65, COX-2, INOS, and ICAM-1) which 
lead to an increase in retinal vascular permeability, intraocular pressure, and vision loss. 
Therefore, treatment with inflammatory inhibitor (JSH-23) will mitigate this vision loss. 
Specific Aims 
Specific Aim 1: To determine whether there is an increase in inflammatory 
mediators (NF- p65, COX-2, INOS, ICAM-1) in Retina of T1D mice and 
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whether inflammatory inhibitor, JSH-23, mitigate this increase in inflammatory 
mediators. (Chapter 3) 
Specific Aim 2: To determine whether T1D increases retinal vascular permeability by 
decreasing expression of junctional molecules (Occludin, Connexin 43) and whether 
treatment with JSH-23 mitigate this increase in retinal vascular permeability. (Chapter 3) 
Specific Aim 3: To determine whether T1D leads to vision loss in part by increase 
retinal vascular permeability and  ocular  pressure and whether treatment with JSH-23 
mitigate this vision loss and retinal vascular permeability. (Chapter 4) 
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CHAPTER III 
JSH-23 DOWNREGULATES NF-B AND INCREASE EXPRESION OF 
JUNCTIONAL MOLECULES IN THE RETINA OF AKITA MICE 
Introduction 
T1D is a chronic illness that is diagnosed during childhood. It occurs in ~1:400-
600 American children [220]. A recent disturbing trend is a 15-20% increase in new 
diagnoses of T1D under age 5 [221, 222]. The reason for this alarming increase in youths 
is debatable. Clinically, diabetes management has proven challenging for a variety of 
reasons, including physiological factors such as increased insulin sensitivity, especially in 
children [223]. T1D microvascular complications included DR which is divided into 
NPDR and PDR. DME can develop in either of the two stages [224]. Other serious 
complications include retinal detachment, and blindness. 
DR is a leading cause of blindness in the working age adults. In its advanced 
form, DR can lead to blindness due to the development of DME, and cataract. Current 
clinical interventions vary depending on the extent of disease progression. Tight blood-
glucose control and dietary measures may help slow down the disease progression in 
some people however; glucose control does not stop disease progression to DME or PDR. 
Patients may require laser surgery to seal the leaking blood vessels in their eyes or to 
discourage other vessels from leaking further. VEGF inhibitor injection into the eye may 
also be needed to decrease unabetted underlying inflammation or to stop the formation of 
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abnormal vessels. Leakage from retinal vessels leads to a fresh wave of inflammatory 
swelling that invariably results in a cloudy or blurred vision. Even worse, a surgical 
procedure may be warranted to repair a detached retina. If left untreated, DR causes 
permanent blindness [225, 226]. 
Current interventions do not adequately address the “retino-vascular” signature 
pathology that underlies the initiation, progression, and maintenance of the DR 
phenotype. Furthermore, they fail to restore loss vision in the majority of patients. The 
etiology of DR is not fully understood although many pathways have been proposed for 
the development of DR pathology such as polyol flux, hexosamine, AGEs, and OS. DR is 
regarded as an inflammatory disease due to the presence of various inflammatory 
mediators found in the vitreous and the retinas of diabetic animals and humans [227]. An 
increase in the expression of inflammatory mediators is directly associated with NF-κB 
activation [120]. NF-B is a dynamic transcription factor that orchestrates complex 
biological processes, including the inflammatory response itself [228]. Owing to its 
upstream role in cell-signaling, NF-κB is considered a central component in the 
inflammatory response, directing the elaboration of cytokines, and responses to stress, 
free radicals, heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial, and viral 
antigens. 
NF-κB is the first responder to harmful stimuli for cells/tissues. It shuttles 
between cytoplasm and nucleus to initiate and then help execute a robust gene-
transcription program. It consists of a family of structurally related transcription factors 
viz. NF-1(p50), and RelA (p65) that can form hetero- and homodimers and translocate 
to the nucleus upon activation [121, 209, 229, 230]. There is a presence of a chronic 
inflammation in diabetics individuals, which could be mediated by dysregulations in NF- 
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 signaling [120]. It has been shown that NF- increased the pro-inflammatory genes 
in the retina of both diabetic animal models and patients [231]. It also induced the 
activation of pyroptosis [194]. It seems that the sustained inflammation could lead to 
degradation of the iBRB. The BRB consists of the iBRB and oBRB which regulates the 
movement of ions, and solutes into the retina. The iBRB maintains harmony between TJ 
molecules, and retinal ECs and any kind of impairments can lead to fluid accumulation in 
the retina [232]. In diabetes, there is a decrease in expression in junctional molecules in 
the presence of sustained inflammation [233]. 
As DR is a significant complication of an underlying autoimmune disease, we 
tested our hypothesis that systemic inhibition of NK-κB activity in a T1D model could 
help mitigate inflammation-induced microvascular changes in the retina that we believe 
are responsible for vision problems. And we know that the inflammatory mediators are 
elevated in the retina of DR; and are associated with iBRB breakdown [234]. Therefore, 
we hypothesized that pre-empting inflammation by inhibiting NK-κB activity with JSH-
23 would certainly help mitigate the microvascular alterations in the diabetic retina. 
Moreover, JSH-23 has been demonstrated to inhibit the nuclear translocation of NF--
p65 and thus inhibit its transcriptional activity [209]. The objective of this study is to 
investigate the effect of how suppressing inflammation could potentially prevent the 
development of DR in the Akita mouse model. 
Methods 
Animal Genotyping and Maintenance of the Animals. Male C57BL/6J (WT) and 
Ins2Akita+/− mice (Akita) were purchased from the Jackson Laboratory (Bar Harbor, ME). 
All animals were ∼24-26 weeks old and were maintained in a 12:12 hour light-dark cycle 
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with a regular mouse diet at the University of Louisville School of Medicine animal 
facility. Mice were cared according to ARVO guidelines, as approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Louisville, Louisville, 
KY. The experimental protocols were performed following the National Institute of 
Health guidelines (NIH Pub. No. 86–23, revised 1985). Genotyping of the mice was 
carried out by collecting the tail biopsy. DNA was isolated using the DNeasy Blood and 
tissue kit (Qiagen, Germantown, MD). The cross‐breeding yielded Ins2Akita  with high and 
low glucose levels, as measured by blood glucose meter Ultra Touch 2 (Life Scan, USA). 
The high glucose level category consists of mice with blood glucose levels that were 
greater than or equal to 300 mg/dL, and the low glucose levels were animals exhibiting 
less than or equal to 250 mg/dL. Only mice with high glucose levels used in the 
experiments. 
Mice were divided into four different groups: (a) WT, (b) WT + JSH-23, (c) Ins2 Akita, 
and (d) Ins2Akita + JSH-23. JSH-23 purchased from Sigma (Sigma Aldrich, St. Louis, 
MO; CAS# 749886-87-1). A stock solution of JSH-23 was prepared by diluting 25 mg in 
1000 microliter (µL) of 200 proofs ethanol (Decon Labs, King of Prussia, PA; CAS# 64-
17-5) and stored at -70 degrees Celsius. A 100 µL of the stock solution diluted with 4900 
µL of 1X sterile phosphate-buffered saline (PBS). The control solution prepared with 
4900 mL of 1X PBS and 100 mL of 200 proofs ethanol. Akita and wild type (WT) 
C57BL/6J mice strains were treated with or without a specific and selective inhibitor for 
the translocation of the NF-κB (i.e. with JSH-23) intraperitoneally (IP) @ 5mg/Kg body 
weight on alternate days for a total of 4 weeks. Blood pressure (CODA Instrument), 
blood glucose (Ultra Touch 2), body weights (OHAUS, CS-2000 Balance), and 




NF-B inhibitor (Fig. 9). 
 
Measurement of body weight, blood glucose, blood insulin, and glucose tolerance test. 
Body weights of all the animals recorded using an electronic weighing balance (OHAUS, 
CS-2000). ELISA. Mouse INSULIN ELISA kit (EMINS) from Thermo Fischer Scientific 
(Waltham, MA)  was used to analyze plasma insulin levels. The test performed according 
to manufacture instructions.  
Intraperitoneal Glucose Tolerance Test. The glucose tolerance test used to measure the 
clearance of an IP injected glucose load from the body and to detect disturbances in 
glucose metabolism that linked to diabetes or metabolic syndrome. Glucose (200 mg/ml) 
was injected IP (@ 2g per kg body weight after 6 hours of fasting. Blood glucose was 
measured (tail vein) at 0, 30, 60, 90, and 120 minutes after the injection using Ultra 
Touch 2 [235].  
 
Reagents and Antibodies. Antibodies and chemicals were purchased from trusted sources 
such as Sigma-Aldrich, Abcam, Cell Signaling Technology, or Santa Cruz 
Biotechnology. Details for the antibodies are; iNOS (ab15323) and NLRP3 (ab214185)  
purchased from Abcam (Cambridge, MA, USA). COX-2 (4842S), Total NF-κB p65 
(8242S), and p-NF-κB p65 (3033S) purchased from Cell Signaling Technology (Danvers, 
MA, USA). ICAM-1 (sc-107) purchased from Santa Cruz Biotechnology (Dallas, TX). 
The secondary antibodies also purchased from Santa Cruz Biotechnology, namely rabbit 
anti‐mouse (sc‐358914), mouse anti‐rabbit (sc‐2357), and mouse anti‐goat (sc‐2354). 
GAPDH (MAB374) was purchased from EMD Millipore (Burlington, MA). All 





Figure 9. Treatment plan. The blood glucose, blood pressure, IOP, and body weight of 
the animals were measured before and after treatment with JSH-23. The treatment was 






Western Blotting. Protein expression profiles were performed via Western blots analyses. 
Retinas were separated from enucleated globes from the euthanized mice, and the retinal 
protein lysates were used immediately or snap‐frozen in liquid nitrogen and stored at –
80°C until further use. Protein were extracted via homogenizing in RIPA buffer (Boston 
BioProducts, Worcester, MA). These cocktails were added to the RIPA buffer; a cocktail 
of 1 mmol/L phenylmethylsulfonyl fluoride (Sigma, Saint Louis, MO), 1% protease 
inhibitors cocktail (Sigma). Then the samples were sonicated with the Sonifier 450 
(Branson Ultrasonics, Danbury, CT). The homogenates were centrifuged at 15,000 
rpm for 15 min at 4°C, and the resultant supernatants were collected and stored at –80°C. 
Bradford assay was used to estimate the total protein contents. Per sample, 40 μg of total 
protein amount resolved on a 10% SDS‐PAGE and then transferred to polyvinylidene 
difluoride (PVDF) membrane. The membranes were incubated with primary antibodies 
overnight and then with the secondary antibodies were added the next day for 3 hours 
before visualization with ECL Luminata Forte (Millipore, Temecula, CA) via a Bio‐Rad 
ChemiDoc system (BioRad Laboratories, Des Plains, IL, USA). Band intensities were 
normalized to GAPDH for all the target proteins analyzed, and their respective 
quantifications were performed through Image Lab™ Software (Bio‐Rad, Hercules, CA). 
 
Quantitative PCR. RNA was isolated with TRIzol® reagent (Life Technologies, 
Carlsbad, CA, USA)  based on the instruction of the manufacturer. Nanodrop-1000 
(Thermo Scientific, Waltham, Ma) was used to analyze RNA quantification and purity. 
Im Prom-II TM Reverse Transcription System (A300, Promega, Madison, WI) was used to 
reverse-transcribe the total RNA into cDNA per instructions of the manufacturer. 
Quantitative PCR (qPCR) was performed for different transcripts  
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(RelA, iNOS, COX-2, ICAM-1, Cx43, Occludin, NLRP3, Casp-1, IL-1). The final 
reaction included 10 l of nuclease-free water, 8 l of Bullseye EvaGreen qPCR 
Mastermix (BEQPCR-S, MIDSCI, Valley Park, MO), 50 picomoles of forward and 
reverse primers, and 1l of cDNA (Table 1). The data were normalized with 
housekeeping gene GAPDH. 
Statistical Analyses. All values are reported as mean ± SEM. One‐way ANOVA was used 
to analyze the difference between the groups, including a Tukey's post hoc analysis for 
groups’ comparisons. The tests were performed with p<0.05 and a total number of mice 
(n) = 5–20 were subjected toanalysis depending upon particular experiments from each 
group. GraphPad Prism (Ver 8.1, GraphPad Software) used during analyses. 
Results 
Confirmation of Ins2Akita Mutation in the Expanded Mouse Colony and Effect of JSH-23 
on Glucose Metabolism. Mice tail DNA samples were analyzed using PCR employing 
specific primers to determine the mice genotype. Genotyping revealed the mutated 
version of the insulin gene exhibiting two discrete bands: 280 and 140 bp representing the 
heterozygous status while wild‐type (WT) mice showed one 140 bp band (Fig. 10A). To 
generate mice for the study, Akita female with low blood glucose (LG) were cross-breed 
with male Akita mice with high glucose (HG). Cross‐breeding yielded Akita progeny
with HG and LG levels as measured by blood glucose (BG) meter Ultra Touch 2 (Life 
Scan, USA).  Only Akita mice with a BG level <300 mg/dL were used in this study. 
Akita mice have a mean BG level of 596.47 mg/dL, significantly higher than C57BL/6J 
BG of 173.47 mg/dL (p<0.0001, n=15 per group). JSH-23 significantly decreased 
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Table 1. Nucleotide sequence. Forward and reverse primers gene sequences for each 
gene analyzed. 
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         TABLE 1 
Gene Forward Sequence Reverse Sequence 
Rel A[236] 5’- GCCCAGACCGCAGTATCC 5’- GTCCCGCACTGTCACCTG 
iNOS [237] 5’- CAGCTGGGCTGTACAAACCTT 5’- CATTGGAAGTGAAGCGGTTCG 
COX-2 [238] 5’- CAGAACCGCATTGCCTCTG 5’- TTGTAACTTCTGGTCCTCATGTCGA 
ICAM-1[239] 5’- TTCACACTGAATGCCAGCTC 5’- GTCTGCTGAGACCCCTCTTG 
Cx43 [240] 5’- CCAAGGAGTTCCACCACTTTG 5’- CCATGTCTGGGCACCTCTCT 
Occludin[241] 5’- AGACCCAAGAGCAGCCAAAG 5’- GGAAGCGATGAAGCAGAAGG 
NLRP3 [242] 5’- CTTCTAGCTTCTGCCGTGGTCTCT 5’- CGAAGCAGCATTGATGGGACA 
Casp-1[242] 5’-GTACACGTCTTGCCCTCATTATCTG 5’- TTTCACCTCTTTCACCATCTCCAG 




Figure 10. Genotyping and Physiological Parameters of Akita, and C57BL/6J Mice. 
A. Genotyping of Akita, and C57BL/6J mice. B. Body weight of the Akita, and the 
C57BL/6J, Akita mice body weights were significantly lower than the body weights of 
the C57BL/6J mice (p<0.0001, n=19 per group). C.  The blood glucose level of Akita, 
and C57BL/6J mice the blood glucose levels of Akita mice were significantly higher than 
C57BL/6J mice (p<0.0001, n=15 per group). JSH-23 significantly decreased blood 
glucose levels in Akita mice (p<0.0001). D. Plasma insulin levels of Akita mice were 
substantially lower (p<0.0001, n=19 per group). E. Intraperitoneal glucose tolerance test 
depicted the inability of the Akita mice to lower their blood glucose levels (p<0.009, n=5 





















Figure 11. Expression of NF-B p65 in the retinae of Akita, and C57BL/6J mice 
after treatment with JSH-23. A. Immunoblotting image of total and phosphorylated 
NF-B p65. B. The total expression level of NF-B p65 was significantly elevated in 
Akita mice (p<0.05, n=7 per group). JSH-23 significantly decreased the total expression 
of NF-B p65 in Akita mice (p<0.005). C. The phosphorylated expression level of NF-
B p65 significantly elevated in Akita mice (p<0.05, n=7 per group). JSH-23 could 
significantly decreased the phosphorylated expression level of NF-B p65 (p<0.05). D.  
The gene expression of NF-B p65 was significantly elevated in Akita mice (p<0.0001, 
n=7). JSH-23 significantly decreased the gene expression of NF-B p65 in Akita mice 


















Figure 12. Expression levels of ICAM-1, iNOS, and COX-2 in the retinae of Akita, 
and C57BL/6J mice after treatment with JSH-23. A. Immunoblotting image of ICAM-
1, iNOS, and COX-2. B. The expression level of ICAM-1 was significantly elevated in 
Akita mice (p<0.0218, n=6 per group). JSH-23 significantly decreased the expression of 
ICAM-1 in Akita mice (p<0.0028). C. The expression level of iNOS was significantly 
elevated in Akita mice (p<0.0001, n=6 per group). JSH-23 significantly decreased the 
expression of iNOS in Akita mice (p<0.0001). D. The expression level of COX-2 was 
significantly elevated in Akita mice (p<0.0001, n=6 per group). JSH-23 significantly 






Figure 13. Gene expression level of ICAM-1, iNOS, and COX-2 in the retinae of 
Akita mice, and C57BL/6J treated with JSH-23. A. ICAM-1 gene expression was  
elevated in Akita mice (p<0.0003, n=5 per group). JSH-23 decreased the gene expression 
in Akita mice (p<0.0001). The iNOS gene expression was elevated in Akita mice 
(p<0.0012, n=5 per group). JSH-23 decreased iNOS gene expression levels in Akita mice 
(p<0.0031). COX-2 gene expression was increased in Akita mice (p<0.0004, n=5 per 
























Figure 14. Pyroptosis Marker in the retinae of Akita, and C57BL/6J mice treated 
with JSH-23. A. Immunoblotting imaging of NLRP3. B. NLRP3 expression level was 
elevated in Akita mice (p<0.018, n=6 per group). JSH-23 decreased NLRP3 expression in 
Akita mice (p<0.0003). C. NLRP3 gene expression was increased in Akita mice 
(p<0.0025, n=6 per group). JSH-23 decreased the gene expression level of NLRP3 in 
Akita mice (p<0.0003). D. Casp-1 gene expression increased in Akita mice (p<0.0001, 
n=6 per group). JSH-23 decreased the gene expression of casp-1 (p<0.0001). E.  IL-1 
gene expression was elevated in Akita mice (p<0.0001, n=6 per group). JSH-23 



















Figure 15. Expression of Junctional Molecules in the retinae of Akita, and C57BL/6J 
mice treated with JSH-23. A. Immunoblotting image of Cx43, and occludin. B. Cx43 
expression was decreased in Akita mice (p<0.0165, n=5 per group). JSH-23 increased the 
expression of Cx43 (p<0.0006). C. Occludin expression was decreased in Akita mice 
(p<0.0068, n=5 per group). JSH-23 decreased the expression of occludin (p<0.0071). D. 
Cx43 gene expression was decreased in Akita mice (p<0.003, n=5 per group). JSH-23 
increased the gene expression in Akita (p<0.0237). E. Occludin gene expression was 
decreased in Akita mice (p<0.0073, n=5 per group). JSH-23 increased the gene 






the mean (456.2 mg/dL, p<0.0001) blood glucose level in Akita mice (Fig. 10C). Akita 
mice have a mean body weight of 26.60g, substantially lower than C57BL/6J mice with a 
mean of 30.82g (p<0.0001). JSH-23 did not have any effect on the mean body weights of 
the Akita mice (Fig. 10B). Akita displayed significantly lower plasma insulin levels 
(p<0.0001) (Fig. 10D). As expected, results from IP administered glucose tolerance test 
(ipGTT) showed high basal glucose levels in Akita in comparison to C57BL/6J mice. 
Furthermore, ipGGT also revealed that the Akita strain was unable to lower its glucose 
level (p<0.0090) in their blood (Fig. 10E).  
 
JSH-23 Diminishes Key Inflammatory Molecules in the Diabetic Retinae.  Western 
blotting and qPCR analyses were used to examine the effects of systemic inhibition of 
NF-κB in mice retinae. The total (p< 0.0353) and phosphorylated amounts (p<0.0463) of 
expression levels of NF-B p65 were elevated in the retinae of Akita mice. NF-B p65 
subunit gene expression (p<0.0001) was also elevated in the retina of Akita mice. JSH-23 
decreased the total (p<0.0053) and phosphorylated (p<0.0254) and gene expression 
(p<0.0002) levels of NF-B p65 (Fig. 11).  
 ICAM-1 expression level (p<0.0218) and the gene expression (p<0.0003) were 
elevated in the retinae of Akita mice. JSH-23 decreased the expression level (p<0.0028) 
and gene expression (p<0.0001) of ICAM-1 in the retinae of Akita mice. The iNOS 
expression level (p<0.0001) and gene expression (p<0.0012) were increased in the retinae 
of Akita mice. JSH-23 decreased the expression (p<0.0001) and gene expression 
(p<0.0031) levels of iNOS in the retinae of Akita mice. COX-2 expression (p<0.0001) 
and gene expression levels (p<0.0004) were increased in the retinae of Akita mice. JSH-
23 decreased expression level  
77 
(p<0.0001) and gene expression levels (p<0.0001) of COX-2 in the retinae of Akita mice 
(Fig. 12 & 13). 
JSH-23 Decreases Expression of Pyroptosis Markers in the Diabetic Retinae. NLRP3 
expression (p<0.0180) and gene expression levels (p<0.0025) were increased in the 
retinae of Akita mice. JSH-23 decreased expression (p<0.0003) and gene expression 
levels (p<0.0003) of NLRP3 in the retinae of Akita mice. The gene expressions levels of 
casp-1 (p<0.0001) and IL-1 (p<0.0001) were increased in the retinae of Akita mice. 
JSH-23 decreased gene expression levels of casp-1 (p<0.0001) and IL-1 (p<0.0001) in 
the retinae of Akita mice (Fig. 14). 
JSH-23 Augments Integrity of the Tight and Gap Junctions Proteins in the Diabetic 
Retinae. Cx43 expression (p<0.0165) and gene expression levels (p<0.0003) were 
elevated in the retinae of Akita mice. JSH-23 increased expression (p<0.0006) and gene 
expression levels (p<0.0237) in the retinae of Akita mice. Occludin expression 
(p<0.0068) and gene expression levels (p<0.0073) in the retinae of Akita mice were also 
modulated as can be seen that JSH-23 increased the expression (p<0.0071) and gene 
expression levels (p<0.0060) of occludin in the retinae of Akita mice (Fig. 15). 
Discussion 
There are several mouse models of T1D induced DR that vary in etiology, 
severity, mode of inheritance, progression, and overall disease pathology. Akita strain of 
mouse becomes diabetic due to a mutation in the insulin 2 (Ins2) gene that results in 




pancreas. This structural alteration in the insulin molecule impairs insulin secretion, OS, 
cell death, and an impairs glucose-stimulated insulin release. This also produces toxic 
byproducts, leading to a severe inflammatory changes in the diabetic retinae causing the 
retinovascular permeability, and leukostasis [144, 216-218, 243]. NF-κB is the first 
responder to harmful stimuli for the cells. Known inducers of NF-κB are ROS, IL-1β, 
bacterial LPS, and ionizing radiation mediated DNA damage [244-248]. NF-κB is a 
family of transcription factors, RelA (p65), that hetero/homodimerize, translocate to the 
nucleus to augment NF-B directed genes’ expression, particularly the inflammatory 
mediators [121]. 
Inflammatory mediators such as iNOS, COX-2, and ICAM-1 are elevated in the 
retinae of DR, associated with iBRB breakdown, thus increasing the retinal vascular 
permeability. Increased leukostasis mediated by ICAM-1 is associated with an increase in 
the vascular permeability [234]. HgA induces leukostasis in retinal vessels in rodents that 
leads to endothelial apoptosis [249-251]. Leukostasis impairs vision via two proposed 
mechanisms: (a) iBRB breakdown due to cellular apoptosis in the endothelium and (b) 
endothelial apoptosis that leads to avascular capillaries; thus, nonperfusion or 
hypoperfusion which in turn results into neovascularization [251]. NF- plays an 
essential role in inflammation and leukostasis via ICAM-1.  
Inflammation of the retinal vasculature was significantly diminished as 
demonstrated by expression analyses of the critical inflammatory mediators such as 
ICAM-1, COX-2, and iNOS in the retinae of Akita mice. Also, the total NF-B p65, and 
pNF-B p65 activities were significantly reduced, indicating a clear readout of the 
specific inhibition of the critical transcription factor that is responsible for mounting  
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immune response in the diabetic retinae. In diabetes, leukocyte adhesion to retinal 
endothelium is the primary mechanism of leukostasis. This adhesion is mediated by the 
upregulation of ICAM-1 due to NF-B activation, which increases ICAM-1 expression. 
Increased leukostasis is associated with enhanced vascular permeability [166-168]. 
Furthermore, inhibition of ICAM-1 has shown to reduce the leakage and leukocytes 
adhesion along with a decrease in leukocytes adherence in diabetic rats [169]. Prominent 
inflammatory mediators like iNOS, COX-2, and ICAM-1 were elevated in the diabetic 
retinas, as shown in this study. These molecules are associated with iBRB breakdown 
leading to an increase in the retinal vascular permeability during diabetes because of the 
chronic inflammation that potentially contributes to iBRB breakdown. It was reported 
that inhibition of NF-B activation by calcium dobesilate prevented degradation of 
occludin in part by decreasing the expression of ICAM-1 [58].  
Similarly, the HgA induced downregulation of Cx43 severely affected the GJIC 
in the blood vessels and that has again been shown to contribute to iBRB integrity during 
DR pathogenesis [252]. Low expression of Cx43 was concurrently associated with other 
companion junctional proteins such as occludin and ZO-1 that were also found to be 
downregulated [195]. Therefore, we analyzed retinal cell lysates for occludin, and Cx43, 
employing Western blotting and qPCR assays. Their expression levels in JSH-23-treated 
Akita mice were increased significantly. JSH-23 was shown to be a protective agent by 
attenuating the loss of Cx43 during the hypoxic environments [253]. Furthermore, others 
have shown that specific inhibition of NF-κB by JSH-23 attenuated the pathological 
sprouting of the lymphatic vessels [254]. NF-B activation also activated the assembly of 
the NLRP3 inflammasome. NLRP3 has been shown to be active during inflammation, 
and activation of inflammasome in the retinae [242, 255, 256]. 
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Pyroptosis, and inflammatory cell death both activate via the assembly of the 
NLRP3 inflammasome that further enables casp-1, which then cleaves the IL-1. Retinal 
vascular cell death during HgA causes the breakdown of iBRB. HgA induced activation 
of casp-1, and IL-1 has been reported in causing Müller cell death [193]. This study 
showed an increase in NLRP3 expression level and the gene expression of casp-1, and 
IL-1 in the retinae of Akita mice.  JSH-23 significantly decreased NLRP3 expression 
levels and the gene expression of both casp-1 and IL-1 in the retinae of Akita mice. 
The incidence of T1D is rising, and glycemic variability is common among 
young children these days. This has long-term implications for health and well-being for 
the diabetics. Research has identified several potential options to cure T1D, but none of 
them have shown any concrete outcome till today. Thus, targeted interventions are 
needed to reduce the risk of long-term T1D-related complications, and improve the 
immediate quality of life in patients. The NF-κB molecule is a critical player in the 
inflammatory process; thus, strategies inhibiting NF-κB has potential therapeutic 
applications in the fight against diabetes. The result of this study showed that the 
sustained long-term inhibition of NF-κB activity could significantly diminish the 
degradation of cell-junctional molecules in the retinae of Akita mice. 
Conclusion: Inflammatory mediators such as ICAM-1, INOS, and COX-2 expression 
were elevated in the retinae of Akita mice. That upregulation of inflammatory mediators 
was associated with the activation of NF-B p65. Elevated levels of inflammatory 
mediators are linked with the degradation of junctional molecules, thus impairing the 
iBRB. JSH-23 decreased NF-B p65 expression levels in the retinae of Akita mice along 
with inflammatory mediators (ICAM1, INOS, and COX-2) expression in the retinae of 
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Akita mice. JSH-23 treatment reduced NLRP3 and other pyroptosis mediators (e.g. casp-
1, and IL-1). Inhibition of NF-B p65 also upregulated the expression of Cx43, and 
occludin in the retinae of Akita mice. Inhibition of NF-B p65 also decreases blood 




EFFECT OF JSH-23 ON VISION IN AKITA MICE 
Introduction 
T1D predisposes patients to long-term complications like kidney failure, 
neuropathy, and blindness. Lately, the incidence of T1D is rising, and glycemic 
variability is becoming more common in the younger population. Although T1D is 
considered an autoimmune disease, it is not clear what exactly causes the immune system 
to attack the beta cells in the pancreas. Up to 90 percent of T1D patients can develop 
retinopathy post-diagnosis; as a result, it is becoming a severe medical problem globally. 
DR is the leading cause of blindness in the working-age adults [250]. Unfortunately, 
there is no cure for DR. 
HgA causes endothelial damage and capillary nonperfusion, ultimately leading to 
retinal hypoxia. This prompts the growth of abnormal blood vessels in the eye. Early 
detection and timely intervention can reduce the risk, but vision loss is irreversible. 
Research in the past has identified several options to treat T1D but not all benefit the 
majority of patients. Thus, more study needed to address the vascular pathology that 
occurs in the retinae. 
HgA is known to cause sustained ROS generation, ATP depletion, ER stress, 
and, finally, inflammation as a complication of DR pathogenesis. This eventually leads to 
microvascular damage, basement membrane thickening, iBRB breakdown, capillary cell 
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death, acellular capillary, neovascularization, and sometimes the detachment of the retina 
itself. 
Inflammatory mediators such as iNOS, COX-2, and ICAM-1 are elevated in the 
retinae of DR, and are associated with iBRB breakdown, thus increasing the retinal 
vascular permeability. Increased leukostasis is related to an increase in vascular 
permeability too [234]. HgA induces leukocytes adhesion in rodents retinal vessels that 
leads to endothelial apoptosis [249-251]. NF- plays an essential role in inflammation, 
and leukostasis via ICAM-1. 
iBRB breakdown is strongly associated with the release of proinflammatory 
factors such as iNOS, and elevated levels of inflammatory markers that play a definitive 
role in raising IOP. Additionally, IOP elevation linked with the upregulation of the 
hypoxia-inducible factor-1 alpha (HIP-1α), interleukins, and VEGF [257]. Inflammation 
contributes to BRB breakdown and thus increases the intraocular pressure (IOP). 
In this study, we decided to inhibit NF-κB, the first responder during the 
inflammation, employing a T1D mouse model and demonstrate that specific targeting of 
the NF- activity could help prevent chronic inflammation that is responsible for the 
degenerative changes in the retinae. Our findings highlight the significance of targeted 
intervention in reducing the long-term diabetic complications and thus improving the 
underlying constant inflammatory milieu that is propagated by chronic metabolic 
dysfunction in the diabetic patients.  
Methods 




was measured with CODA noninvasive blood pressure instrument (Kent Scientific,  
Torrington, CT). The IOP was recorded by a Tonometer (iCare, Tonolab). Both pressure 
were measured before and after the JSH-23 treatment in mice [258]. 
 
Fluorescein Angiography. Mice injected by IP with 100 µl of AK-FLUOR® (NDC 
17478-253-10, Akorn, Inc, Lake Forest, IL) after induction of anesthesia with 300 cc of 
2x tribromoethanol (TBE). The fundus was visualized by Micron IV microscope 
(Phoenix Technology Group, Pleasonton, CA). Images were analyzed via ImageJ for the 
presence of fluorescence outside of the retinal capillaries [259] .  
 
In vivo Electroretinography (ERG), and Optical Coherence Tomography (OCT). 
Electroretinograms (ERGs) were performed on C57BL/6J and Akita age-matched mice. 
Briefly, mice were dark-adapted overnight, and anesthetized by IP using TBE. After 
pupils were dilated, full-field scotopic ERGs were recorded using the Tucker–Davis 
System Workstation (Tucker–Davis Technologies, Alachua, FL) for the real-time 
visualization of the averaged a- and b-waves. The BioSigRZ system was used for the 
quantification, and further analysis. OCT was performed to measure the anatomical 
differences in the retinal layers before and after treatment with JSH-23, employing the 
Image-Guided OCT2 equipment (Phoenix Technology Group, Pleasonton, CA)  
 
Light-dark Box Chamber Test. The animals were subjected individually one by one for the 
light-dark box test into the light chamber with the light close. Then, PACS Shuttle Box 
Version 3.40 was set up with Experiment Mode as “Passive Avoidance”, UCS Grid 
Intensity (Amperes): 0, Exploration duration: 30  
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seconds, Maximal Trial Duration: 5 minutes, CS Light Intensity: 10 volts, UCS Grid 
Duration: 2 seconds. After 30 seconds of exploration, the light flickered on. Then the time 
it took the mice to transfer from the light chamber to the dark was measured [260]. 
Statistical Analyses. All the values are reported as mean ± SEM. One‐way ANOVA was 
used to analyze the difference between the groups, including a Tukey's post hoc analysis 
for groups’ comparisons. The tests were performed with p<0.05 and a total number of 
mice (n) = 5–20 were subjected to experimentations from each group. GraphPad Prism 
(Ver 8, GraphPad Software) was used during the subsequent analyses. 
Results 
Monitoring of Systemic Blood Pressure and Intraocular Pressure. We next evaluated 
systemic and IOP before and after JSH-23 treatment. It is known that JSH-23 increases 
blood pressure in hypertriglyceridemic (HTG) rats [261], therefore; we sought to 
determine whether JSH-23 did any alteration to the mice systemic blood pressure. To find 
that out, we subjected treated and untreated mice to a noninvasive tail-cuff method for 
recording blood pressure. None of the mice acquired showed any statistically significant 
change in their blood pressures. For example, the mean blood pressure in Akita mice was 
117.15 mmHg, and for C57BL/6J strain it was 90.17 mmHg. JSH-23 did not have any 
effect on the treated Akita mice with a mean of 102.7 mmHg (Fig. 16A). The mean IOP 
of the Akita mice was 25.33 mmHg vs. 14.55 mmHg for C57BL/6J (p<0.0001, n=12 per 
group). However, JSH-23 did decrease the IOP in Akita mice, 16.02 mmHg (p<0.0001) 
(Fig 16B). 
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Figure 16. Systemic Blood Pressure and Intraocular Pressure (IOP) in Akita and 
C57BL/6J mice strains. A. JSH-23 does not affect the systemic blood pressure (n= 8 per 
group). B. IOP was elevated in Akita mice (p<0.0001, n=12 per group) and JSH-23 






Figure 17. Fundus imaging of Akita, and C57BL/6J treated with JSH-23. The retinae 
of Akita mice depicted derailment in their vasculature network and the treatment with 


























Figure 18. Fluorescence Angiography in Akita, and C57BL/6J strains treated with 
JSH-23. The retinae vasculature of Akita mice showed an increased vascular 
permeability (p<0.0001, n=6 per group). And treatment with JSH-23 decreased the 






Figure 19: Optical Coherence Tomography in Akita, and C57BL/6J treated with 
JSH-23.  The retinal layer’s thickness decreased in Akita mice (p<0.0001, n=5 per 




























Figure 20: Electroretinogram of Akita, and C57BL/6J mice strains treated with 
JSH-23. A. Electroretinograms of C57BL/6J, and Akita mice treated and non-treated 
with JSH23. B. Electroretinograms superimposed on top of each other on excel 
spreadsheet  C. Amplitude of A-wave in the retinae of Akita was found to be decreased 
(p<0.0001, n=6 per group) and the treatment with JSH-23 prevented this decrease in the 
A-wave amplitude in Akita (p<0.0001). D. The amplitude of B-wave in Akita mice was 
also decreased (p<0.0001, n=6 per group) aand treatment with JSH-23 could prevent this 






















Figure 21: The light-dark chamber movement analysis of Akita and C57BL/6J mice treated 
with JSH-23. A. Assessment of vision-guided behavior employing a light-dark chamber, it took 
Akita mice significantly longer to move from the dark to the light chamber (p<0.0001, n=8 per group) 
relative to C57BL/J6. Akita treated with NF-kB inhibitor demonstrated significantly decrease time 




Assessment of Retinal Fundus. The retinal fundus images of Akita mice depicted the 
degeneration of the retinal blood vessels along with yellow spots that appeared to be 
cellular debris like structure and the treatment with JSH-23 seemed to prevent the 
degeneration of these inflamed retinal blood vessels in Akita mice post treatment (Fig. 
17). 
Assessment of Retinal Vasculature by Fluorescein Angiography (FA) and Fundoscopy. 
Retinal complications such as vascular damage is consistent with T1D. We know that 
HgA-led inflammation causes retinal vascular leakage, and microaneurysm formation. 
We studied the anti-inflammatory effects of JSH-23 on the retinal vasculature employing 
in vivo FA [218]. The results showed diminished retinal permeability in the JSH-23 
treated mice (p<0.0001, n=6 per group) (Fig. 18). Interestingly, a decrease in perfusion 
time (time is taken by fluorescein isothiocyanate; FITC dye to perfuse the retinal 
vasculature completely) in Akita mice of about 2 minutes was observed after an IP 
injection of the dye. There was also an increase in microaneurysm formation in the Akita 
mice as expected (Fig. 18). 
In vivo Electroretinography and Optical Coherence Tomography (OCT). Functional 
changes in the retinae was evaluated by full-field scotopic electroretinograms (ERGs) on 
C57BL/6J, and Akita mice employing the BioSigRZ system. Akita mice demonstrated 
widened and truncated A and B waves in contrast to the sharp A, and B waves in 
C57BL/6J mice strain. ERGs of treated, and non-treated of Akita and C57BL/6J showed 
in Fig 20A and Fig.20B. Also, the A-wave was significantly reduced in Akita mice 
compared to WT (p<0.0001 n=6 per group). The average amplitude for Akita mice was 




66.18 V of thw C57BL/6J mice. JSH-23 did increase the magnitude of the A-wave in 
Akita mice, as shown by mean value of 61.75 mV (p<0.0001) (Fig. 20C). On the other 
hand, the B-wave amplitude showed a significant difference between Akita, and 
C57BL/6J strains e.g. 103.78 V vs. 207.53 V (p<0.0001, n=6 per group). JSH-23 
treatment increased the amplitude, and mean of 150.2 mmHg (p<0.0001) (Fig. 20D).  
Retinal structural integrity was evaluated employing real-time, image-guided OCT in 
Akita strain that displayed hyporeflective retinal lucency (blue arrows) along with 
abnormal thickening of the membrana limitans interna, inner nervous stratum opticum, 
and GCL. The retinal thickness layer was reduced in the Akita strain with a mean of 
128.58 m, and 254.25 M C57BL/6J mice (p<0.0001, n=5 per group). JSH-23 
prevented degradation of the retinal thickness layer in Akita mice, as reflected by the 
mean value of 254.25 (p<0.0001) (Fig. 19C).  
 
Evaluation of Vision Guided Behavior in JSH-23 Treated Mice 
Finally, the mice were evaluated for their vision-guided behavior employing a light-dark 
chamber analysis. It took Akita mice significantly longer to move from the dark to the 
light chamber (p<0.0001, n=8 per group) relative to C57BL/J6. The results revealed that 
Akita mice treated with JSH-23 demonstrated significantly decreased time taken by them 





We hypothesized that activation of NF-κB, and its nuclear translocation could be  
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separated from other biological processes, thus giving us an opportunity to test the 
potential strategy of targeting specifically NF-κB activity for a longer duration on a 
sustained basis, and study its beneficial effect(s) in a well-characterized T1D mouse 
model. The model exhibits degenerative changes in the retinal architecture, including its 
blood vessels leading to the development of symptoms mimicking DR pathology [262]. 
By this account, treatment with inflammatory inhibitor such as JSH-23 should in 
principle, prevent the development of DR phenotype. To test this hypothesis, C57BL/6J 
and Ins2Akita (Akita) strain of mice were treated with JSH-23 or without for a total period 
of four weeks continuously. Several disease indicators, such as IOP, blood pressure, 
visual function, were evaluated systematically one by one. For assessing the structural, 
and functional aspects of the retinae methods such as FA, OCT, and ERG with or without 
JSH-23 treatment were employed. Our findings revealed that JSH-23 significantly 
decreased the retinal vasculopathy in the diabetic retinae, and retinal structure was 
successfully protected as evidenced by OCT, and a concurrent decrease in 
the vascular leakage as shown by fundus photography and FA analyses. Further, the data 
indicated that visual function were affected in the Akita mouse and is consistent with 
previously described results [218]. Similar changes in the mouse models of hypertension, 
and retinal neovascularization depicted severe capillary non-perfusion, vessel 
constriction, beading, neovascularization, fibrosis, and edema that have been reported in 
the literature [263]. These changes are associated with inflammation and activation of 
NF-B. Our findings indicate that mitigation of DR severity and its pathology are 
possible via timely inhibition of inflammation on a sustained basis using a selective 
inhibitor of inflammation. 
Chronic inflammation during diabetes is associated with iBRB breakdown that 
leads to an increased retinal vascular permeability, and thus elevate IOP, thereby 
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decreasing vascular permeability. In our study the IOP also improved, as did visual 
function which were revealed by the ERG analyses when inflammation was successfully 
arrested. Notably, the inflammatory response to injury has also been shown to be 
effectively attenuated by the JSH-23 treatment in another model system, as well [264]. In 
a nutshell, this study advances our understanding of the role of inflammation in DR, and 
sheds important light on one of the approaches to further reduce the inflammatory insults 
in a privileged organ-like the eye. However, additional studies are needed on how best to 
deliver the JSH-23 therapeutically in a clinical setting or its more potent versions directly 
into the eye in a longer-acting fashion. The results did show diminished retinal 
permeability in the JSH-23 treated mice, again confirming that inhibition of inflammation 
via NF-κB inhibition could help protect the retinal vasculature in the diseased eyes. 
Therefore, the results from the present work indicate that mitigation of DR severity, in 
fact, is possible via inhibition of inflammation using a selective inhibitor. 
Conclusions.  Treatment with JSH-23 successfully decreased IOP in Akita mouse strain 
without change in systemic BP noticed. One of the significant findings that came out of 
this work is that the inhibition of inflammation perhaps helped improve the vision in 
Akita mice thus indicating that controlling inflammation could potentially decrease 
retinal inflammatory insults, and therefore improve the structural, as well as, functional 




T1D or insulin-dependent diabetes is a chronic illness that is usually diagnosed 
during childhood [220-222]. Clinically, diabetes management has proven challenging for 
a variety of reasons including physiological factors such as increased insulin sensitivity, 
especially in children [223]. T1D leads to the degeneration of microvascular network. DR 
costs the US government 1/2 a billion dollar in medical cost every year [265]. According 
to the National Eye Institutes (NEI), in 2010 there were approximately 7.7 million 
individuals living with DR, and that number is projected to double by 2050. Although 
more Caucasians are affected by the disease, it is more common in African-Americans 
and Hispanics communities [266]. DR affects both type I and type II DM patients, 
however DR is twice more common in T1D [225]. 
DR is the leading microvascular damage in Diabetes. It is defined by leakage of 
the blood and other body fluids into the retinae from nearby microvessels followed by 
abnormal angiogenesis, increase in permeability, micro aneurysms, loss of pericytes, and 
thickening of the basement membrane [226]. DR starts as NPDR, gradually progresses to 
DME and or PDR [224]. NPDR is characterized by the presence of hemorrhage, 
microaneurysms, abnormality in the retinal microvessels, and the cotton wool spots 
(fluffy white patches in the retina). On the other hand, PDR is characterized as an 
abnormal growth of blood vessels in the retina [267]. Untreated DR could develop into 
DME (fluid accumulation into the macula) or PDR (meovascularization). DME not 
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PDR is more prevalent in type II diabetes [268]. Other complications of DR include 
retinal detachment. The development of vessels’ growth into the area that drains fluid 
from the eye raises IOP to the point that can damage the optic nerve. If left untreated, 
PDR causes severe vision loss or even blindness. 
Treatment of DR depends on the stage of the disease itself since the goal remains 
to slow or stop further disease progression. Many times, laser (photocoagulation) is used 
to create burns in the retina to seal the leaks in order to avoid further leakage. Injections 
of drugs (anti-vascular endothelial growth factor) in the eye are aimed at stopping the 
vascular leakage and new vessel formation. These approaches, along with tight blood-
glucose control and dietary measures, may help slow down disease progression in some 
people [225, 226]. Current interventions do not adequately address the “retino-vascular” 
signature pathology that underlies the initiation, progression, and maintenance of the DR 
phenotype. Furthermore, they fail to restore vision in the majority of patients. The 
etiology of DR is not fully understood despite an abundance of literature describing the 
impact of the polyol flux, hexosamine pathways, AGEs, and OS. However, recently, DR 
is regarded as a stand-alone inflammatory disease due to the presence of various 
inflammatory mediators that have been repeatedly found in the vitreous and retinas of 
both diabetic animals and humans [227]. Inflammation is a response of the immune 
system after an injury had occurred or to a foreign entity. The resolution of inflammation 
involves cytokines, which upregulate pro-inflammatory proteins [269]. There is a 
consistent presence of a chronic inflammatory environment in the diabetics individuals, 
which could be mediated by dysregulation of the master regulator i.e. NF-. 
Interestingly, a substantial increase in the expression of inflammatory 
markers/molecules is directly associated with NF-κB [120], a dynamic transcription 
factor that orchestrates complex biological processes, including the inflammatory 
105 
response itself [228]. Owing to its upstream role in cell-signaling, NF-κB is considered as 
a central component in the inflammatory response [121, 209, 229, 230]. Dysregulations 
of NF- induces overexpression of inflammatory mediators (iNOS, ICAM-1, COX-2) 
in the retinas of diabetic animal models and patients [231]. It induces activation of 
pyroptosis process (NLRP3, IL-1) [194]. This sustained inflammation could easily lead 
to degradation of the iBRB in many susceptible individuals leading to a substantial 
decrease in the expression of junctional molecules such as Cx43, and occludin [233]. 
Furthermore, iBRB impairments also contributes to fluid accumulation in the retina 
[232]. 
There is an increase in inflammatory mediators (NF- p65, COX-2, INOS, and 
ICAM-1) in the retina of T1D mice. These mediators are associated with decreasing the 
expression of junctional molecules (occludin, and Cx43) leading to iBRB impairment, 
increased retinal vascular permeability, and increase in the ocular pressure. The objective 
of this study was to investigate whether treatment with JSH-23 mitigates this vision loss 
and retinal vascular permeability, thus potentially preventing the development of DR. We 
therefore hypothesized that pre-empting inflammation by systemically inhibiting NK-κB 
activity with, JSH-23 could mitigate microvascular alterations in the diabetic retinae. 
Findings from this study suggest that decreasing the inflammation alone could 
protect the diabetic retinae and its vascular network highlighting the fact that regulating 
NK-κB may have broad implications in treating chronic inflammatory diseases, including 
diabetes and its devastating complications. This study showed a decrease in the blood 
glucose of Akita mice after treatment with JSH-23. This decreased in blood glucose level 
could be due to increase in insulin sensitivity, byproduct of suppressing inflammation. 
JSH-23 decreased the inflammatory mediators (NF-B p65, ICAM-1, iNOS, COX-2) in 
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the retinae of Akita mice. It also reduced pyroptosis markers (NLRP3, Casp-1, and IL-
1) in the retinae of Akita mice. More importantly, JSH-23 also reduced the degradation 
of junctional molecules in the retina of Akita mice (occludin, and Cx43). Not only it also 
decreased retinal vascular permeability, IOP, in Akita mice but also increased A-wave 
and B-wave in Akita mice. 
In this study we conclude that during T1D, vision loss is due to retinal vascular 
leakage by an increase in inflammatory mediators (NF-B p65, COX-2, INOS, and 
ICAM-1), which leads to an increase in retinal vascular permeability, IOP, and the 
vision-loss. Treatment with an inflammatory inhibitor (JSH-23) most likely helped 
improve vision in Akita as scored via the vision-guided behavioral test. 
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Figure 22. Summary. Inhibitor of inflammation (employing the JSH-23) improved 
visual function by decreasing the retinal vascular permeability, intraocular pressure, and 





The resident immune cells of the retina are called microglia. They help stabilized 
or maintain the homeostasis of the retinal environment. They reside in multiple cell layers 
include the IPL, OPL, and the GCL [59]. Microglia exists physiologically into two states: 
activated or surveying. It contains receptors for many different neuromodulators or 
neurotransmitters such as glutamate, dopamine, bradykinin, and norepinephrine. 
Microglia also secretes many substances in responses to injury, inflammation, or 
constitutively; NO, ROS, cytokines, and chemokines [59]. 
Microglial activation is due to extracellular signals, including cell death, 
neurodegeneration, nucleic acids, which are recognized via TLRs, which then activate the 
pro-inflammatory pathway of NF-B, followed by upregulation of inflammatory 
mediators [270]. Microglia are enabled in DR, although the mechanism is still at large. 
Some studies in diabetic rats showed that HgA does not change the density of microglia, 
but more of them are activated. In human DR patients, the number of microglia 
significantly increases, and they migrate towards injured areas such as micro-aneurysms. 
Thus, it is still yet to be clear whether microglia in DR in part are protective [270]. Upon 
activation, microglia function in presentation of antigen, producing inflammatory 
markers, and phagocytoses. Active microglia could also become self-destructive via 
inducing the death of retinal cells [271]. 
HgA activates microglia via increased ROS, which then enables NF-B. NF-B 
increases the expression of its pro-inflammatory genes, including IL-1, and ICAM-1 
[270].  Hui-yang Zeng et al. reported microglia were activated around the retinal vessels 
in the retina of diabetic patients. Activated microglia released IL-1 and other 
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proinflammatory mediators, which further impaired the retinal vasculature [272], mainly 
via activation of NF-B [273]. In STZ induced rats, Xiaofei Chen et al. found to be a 
redistribution of microglia cells in the retinal layers, with the GCL and the NFL depicting 
an increase in the microglia populations. In contrast, the IPL has the opposite effect, 
which induced retinal thickening [274]. Anti-inflammatory agents, minocycline, was 
shown to prevent retinal neuronal cell death in STZ-induced rats by inhibiting the 
activation and proliferation of microglial cells [275]. 
Literature reported on JSH-23 effect focused on immune cells (Macrophages 
RAW 264.7). JSH-23 effect on microglial activation in the retinae would be critical to 
study the impact on JSH-23 on retinal inflammation. Interestingly, there is no study on 
the effect of JSH-23 directly on retinal ECs or pericytes. 
They are other factors that this study did not take into account that could also 
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1. Rubens P Homme, Naira Metreveli, Sudhakar Veeranki, and
Suresh Tyagi, Exercise ameliorates the development of diabetic
retinopathy, FASEB, Volume 31, Apr 2017
2. Rubens P Homme, Mahavir Singh, Avisek Majumder, Akash
George, Suresh Tyagi, Inhibition of Inflammation and Pyroptosis
mitigate Diabetic Retinopathy via Suppressing Receptor Activated
NF-kB Ligand (RANK-l), Volume 32, 01 Apr 2018
3. Akash K. George, Mahavir Singh, Rubens P Homme, Avisek
Majumder, and, Suresh Tyagi, Role of Hydrogen Sulfide (H2S) on
Homocysteine Mediated Glutamate Excitotoxicity, Endoplasmic
Reticulum Stress and Pyroptosis in Retina, Volume 32, Apr 2018
4. Rubens P Homme, Laha Anewesha, Avisek Majumder, Akash K.
George, Mahavir Singh, and Suresh Tyagi, NF-kB p65 Subunit
Inhibitor: JSH-23 mitigates Diabetic Retinopathy via Reducing
Oxidative Stress, FASEB, Volume 33, April 2019
5. Avisek Majumder, Mahavir Singh, Akash K. George, Rubens P
Homme, Naira Metreveli, Suresh Tyagi, Lactobacillus rhamnosus
GG improves skeletal muscle fatigability in a mouse model of
hyperhomocysteinemia, FASEB, Volume 33, April 2019
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6. Akash K. George, Mahavir Singh, Avisek Majumder, Rubens P
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Hyperhomocysteinemia and the effects of Lactobacillus rhamnosus
GG on cardiac functions in CBS+/- mice, FASEB, Volume 33,
April 2019
7. Mahavir Singh, Akash K. George, Rubens P Homme, Avisek
Majumder, Laha Anewesha, Naira Metreveli, Sathnur B
Pushpakumar, Suresh Tyagi, Probiotic supplementation mitigates
vascular remodeling in the Retina, FASEB, Volume 33, April 2019
Manuscripts: 
1. Rubens PH, Mahavir S, Avisek M, Akash KG, Kavya N,
Harpal SS, Neetu T, David L, and Suresh CT, Remodeling of
Retinal Architecture in Diabetic Retinopathy: Disruption of
Ocular Physiology and Visual Functions by Inflammatory
Gene Products and Pyroptosis, Frontiers in Physiology, Aug
2018 
2. Avisek M,  Mahavir S, Akash K G, Rubens PH, Laha A., and
Suresh CT, Remote ischemic conditioning as a cytoprotective
strategy in vasculopathies during hyperhomocysteinemia: An
emerging research perspective, Journal of Cellular
Biochemistry, Sep 2018
3. Akash KG, Mahavir Singh, Rubens PH, Avisek M, Harpal SS,
and Suresh CT, A hypothesis for treating inflammation and
oxidative stress with hydrogen sulfide during age-related
macular degeneration, International Journal of Ophthalmology,
May 2018
4. Mahavir Singh, Akash KG, Rubens PH, Avisek M, Laha A.,
Harpal SS, and Suresh CT, Circular RNAs profiling in the
cystathionine-β-synthase mutant mouse reveals novel gene
targets for hyperhomocysteinemia induced ocular disorders,
Experimental Eye Research, May 2018
5. Akash KG, Rubens PH, Avisek M, Suresh CT, and Mahavir S,
Effect of MMP-9 gene knockout on retinal vascular function,
Physiology Genomics, December 2019
6. Hardin SJ, Mahavir S, Eyob W, Molnar JC, Rubens PH,
Akash KG, and Suresh CT, Diet-induced chronic syndrome,
metabolically transformed trimethylamine-N-Oxide, and the
cardiac dysfunctions, Reviews in Cardiovascular Medicine,
September 2019
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CT, and Mahavir S, Genes and genetics in
hyperhomocysteinemia and the “1-carbon metabolism”:
implications for retinal structure and eye functions, Journal of
Physiology and Pharmacology, February 2020
9. Laha A, Mahavir S, Akash KG, Rubens PH, and Suresh CT,
Dysregulations of 1-carbon metabolism and muscle atrophy:
potential roles of forkhead box O proteins and PPARy co-
activator-1a, Canadian Journal of Physiology and
Pharmacology, November 2019
10. Akash KG, Rubens PH, Avisek M, Laha A, Metreveli N,
Sandhu HS, and Suresh CT, Hydrogen sulfide intervention in
cystathionine-b-synthase mutant mouse helps restore ocular
homeostasis, International Journal of Ophthalmology, May
2019 
11. Akash KG, Master K, Avisek M, Rubens PH, Laha A, Sandhu
HS, Suresh CT, and Mahavir S, Circular RNAs constitute an
inherent gene regulatory axis in the mammalian eye and brain,
Canadian Journal of Physiology and Pharmacology, June 2019
12. Mahavir S, Akash KG, Rubens PH, Avisek M, Laha A,
Sandhu HS, and Suresh CT, Expression analysis of the circular
RNA molecules in the human retinal cells treated with
homocysteine, Current Eye Research, March 2019
Poster: 
1. Rubens Petit Homme, Naira Metreveli, Sudhakar Veeranki, and
Suresh Tyagi, Exercise ameliorates the development of diabetic
retinopathy, Experimental Biology, April 2017, Chicago
2. Rubens Petit Homme, Akash George,Mahavir Singh, and Suresh
Tyagi, Modulation of Inflammatory Pathway mitigates Diabetic
retinopathy, Kentucky Physiological Society,  April 2018,
Louisville
3. Rubens Petit Homme, Mahavir Singh, Avisek Majumder, Akash
George, and Suresh Tyagi, Inhibition of Inflammation and
Pyroptosis mitigate Diabetic Retinopathy via Suppressing
Receptor Activated NF-kB Ligand (RANK-l), Experimental
Biology, April 2018, San Diego
4. Rubens Petit Homme, Laha Anewesha, Sashi Papu John, Avisek
Majumder, Akash George, Mahavir Singh, and Suresh Tyagi, JSH-
23 Mitigates Diabetic Retinopathy via Reducing Oxidative Stress,
Kentucky Physiology Society, March 2019, Northern Kentucky
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Oxidative Stress Mechanisms in Diabetic Retinopathy,
Experimental Biology, April 2019, Orlando
Presentation: 
1. February 2019. Spencer Symposium, Florida Southern College
Department of Chemistry and Physics Lakeland FL. Stopping
Inflammation Could Prevent Diabetic Retinopathy.
2. March 2019. Physiology Seminar Series, University of Louisville
School of Medicine Department of Physiology, Louisville KY.
Modulation of Inflammatory Pathway by Inflammation Inhibitor
(JSH-23) mitigates Diabetic Retinopathy
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